sibutramine has been researched along with Weight Loss in 295 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 9.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 9.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "To evaluate the effect of sibutramine on weight loss in obese adolescents." | 9.19 | [The effect of sibutramine on weight loss in obese adolescents]. ( Cominato, L; Damiani, D; Franco, RR, 2014) |
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 9.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 9.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "Body weight reduction was greater in the sibutramine group." | 9.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 9.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants." | 9.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 9.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 9.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 9.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Obese patients have high plasma leptin concentrations that do not induce the expected responses on weight regulation, suggesting a leptin resistance in obesity." | 9.13 | Sympathetic-leptin relationship in obesity: effect of weight loss. ( Böhme, P; Quilliot, D; Zannad, F; Ziegler, O, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women." | 9.12 | Influence of weight reduction by sibutramine on female sexual function. ( Kang, HC; Kim, KK; Kim, SS; Youn, BB, 2006) |
| "To describe our experience using sibutramine in weight reduction treatment of adolescents suffering from morbid obesity." | 9.12 | Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. ( Afriat, R; Bortnik, O; Goldman, M; Reisler, G; Tauber, T, 2006) |
| "In this randomized, double-blind, placebo-controlled study, the effect of sibutramine and cognitive-behavioural weight loss (cognitive-BWL) treatment was assessed in obese subjects with and without subclinical binge eating disorder (sBED)." | 9.12 | Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. ( Bauer, C; Fischer, A; Keller, U, 2006) |
| " Sibutramine, a serotonin and norepinephrine transporter blocker, is widely used as an adjunctive obesity treatment, but its impact on endothelial function in obese patients with CAD has not yet been investigated." | 9.12 | Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. ( Beigel, R; Feinberg, MS; Freimark, D; Matetzky, S; Shechter, M, 2006) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 9.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| " The aim of this study was to test weight loss and impact on QoL after sibutramine treatment in obese subjects." | 9.12 | Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. ( Bissoli, L; Bosello, O; Cancelli, F; Di Francesco, V; Mazzali, G; Minniti, A; Sacco, T; Salanitri, T; Zamboni, M; Zoico, E, 2007) |
| "Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype." | 9.12 | Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. ( Baxter, KL; Burton, DD; Camilleri, M; Clark, MM; Graszer, KM; Jensen, MD; Kalsy, SA; Tepoel, DA; Vazquez Roque, MI; Zinsmeister, AR, 2007) |
| "Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients." | 9.12 | Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. ( Apovian, CM; Aronne, LJ; Blakesley, V; Cwik, KM; Early, JL; Fernstrom, MH; Frank, A; Greenway, FL; Heber, D; Hewkin, AC; Kushner, RF; Walch, JK, 2007) |
| "Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy." | 9.12 | NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. ( Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S, 2007) |
| "To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index >or= 30 and < 40 kg/m(2)." | 9.11 | Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. ( Hauner, H; Kurscheid, T; Lauterbach, K; Meier, M; Wendland, G, 2004) |
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 9.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 9.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| "Sibutramine induced greater weight reduction than placebo (6." | 9.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 9.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "Weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months." | 9.11 | Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. ( Mathus-Vliegen, EM, 2005) |
| " Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss." | 9.10 | Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. ( Boivin, JM; Bruntz, JF; Drouin, P; Gille, B; Grentzinger, A; Hammadi, M; Hanotin, C; Igau, B; Zannad, F, 2002) |
| "To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program." | 9.10 | Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. ( Berkowitz, RI; Cronquist, JL; Tershakovec, AM; Wadden, TA, 2003) |
| "Seven adult subjects who had problems with binge eating (mean age, 42 years) were randomly assigned to receive alternating sibutramine and placebo in a double-blind placebo-controlled crossover study." | 9.10 | Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. ( Burgard, MA; Crosby, RD; de Zwaan, M; Gosnell, BA; Mitchell, JE; Roerig, JL; Wambach, BN; Wonderlich, SA, 2003) |
| "The objective of the study was to identify determinants of long-term success in weight maintenance in obese subjects who completed the Sibutramine Trial on Obesity Reduction and Maintenance (n = 261), a multicenter European study of weight loss and weight maintenance in obesity that combines sibutramine treatment with dietary restriction and advice on exercise and behavior." | 9.10 | Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). ( Astrup, AV; Finer, N; Hilsted, J; James, WP; Kopelman, PG; Rössner, S; Saris, WH; van Baak, MA; Van Gaal, LF; van Mil, E, 2003) |
| "To assess the effect of sibutramine-assisted weight reduction program on insulin sensitivity and metabolic parameters in obese normal glucose tolerant individuals over a period of 24 weeks." | 9.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 9.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 9.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 9.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 9.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months." | 9.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "The aim of the present study was to evaluate the cerebrospinal fluid (CSF)/serum leptin ratio during pharmacological therapy for obesity with centrally and peripherally acting drugs." | 9.10 | The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. ( Boguszewski, CL; De Almeida, SM; Niclewicz, PA; Radominski, RB; Rodrigues, AM; Suplicy, Hde L, 2002) |
| "Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with 1 of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily." | 9.09 | Sibutramine produces dose-related weight loss. ( Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999) |
| "Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year." | 9.09 | Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. ( Apfelbaum, M; Hanotin, C; Leutenegger, E; Thomas, F; Vague, P; Ziegler, O, 1999) |
| "Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function." | 9.09 | A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000) |
| "To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b." | 9.09 | Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000) |
| ") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53." | 9.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| "In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects." | 9.09 | Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. ( Astrup, A; Finer, N; Goulder, M; Hansen, D; Hilsted, J; James, W; Kopelman, P; Rössner, S; Saris, W; Toubro, S; Van Gaal, L, 2001) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 9.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and enhance the effects of a low-calorie diet for up to a year." | 9.09 | [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial]. ( Astrup, AV; Hansen, DL; Hilsted, JC; Porsborg, PA; Toubro, S, 2001) |
| "The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity." | 9.09 | Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001) |
| "To evaluate the insulin, leptin, and abdominal adiposity relation during weight loss in patients with upper body obesity." | 9.09 | Insulin-leptin-visceral fat relation during weight loss. ( DeShields, S; Elashoff, R; Go, VL; Heber, D; Hershman, JM; Liu, Y; Wang, HJ; Yip, I, 2001) |
| "In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels." | 9.09 | Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001) |
| "To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons." | 9.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent." | 9.08 | Effects of sibutramine on resting metabolic rate and weight loss in overweight women. ( Bessesen, DH; Hill, JO; Seagle, HM, 1998) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 8.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutramine for the short term on safety and efficacy for weight loss." | 8.84 | Sibutramine: current status as an anti-obesity drug and its future perspectives. ( Henderson, DC; Sharma, B, 2008) |
| " Sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4-5 kg, but is associated with increases in blood pressure and pulse rate." | 8.84 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. ( Majumdar, SR; Padwal, RS, 2007) |
| "This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine)." | 8.84 | Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. ( Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA, 2007) |
| "To investigate, through a meta-analysis of clinical trials, the effect of two weight-reducing drugs, such as orlistat and sibutramine, on serum lipid profiles in overweight and obese subjects, independently of weight loss." | 8.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| " The summary mean differences in weight loss, sibutramine minus placebo, for the 3-month and 1-year trials were -2." | 8.82 | The efficacy and safety of sibutramine for weight loss: a systematic review. ( Arterburn, DE; Crane, PK; Veenstra, DL, 2004) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 8.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet." | 8.81 | The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002) |
| "Sibutramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which induces weight loss via a dual mode of action: enhancing both satiety and energy expenditure." | 8.80 | Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. ( De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 8.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Sibutramine is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which causes weight loss in laboratory rodents via effects on both food intake and metabolic rate." | 8.79 | Sibutramine: a review of the pharmacology of a novel anti-obesity agent. ( Stock, MJ, 1997) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 7.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| "Despite a surprising decision of the European Drug Agency to suspend the registration of sibutramine in the whole of Europe since January 2010 we can state that in our patients we have proven a positive effect of sibutramine substitution on their weight reduction (Tab." | 7.79 | The role of sibutramine in weight reduction. ( Drahokoupilova, E; Fajfrova, J; Pavlik, V; Slovacek, L, 2013) |
| "Assess body mass index (BMI) reduction through a multidisciplinary intervention with sibutramine in adolescents of military parents and examine characteristics and behavioral traits as predictors of successful weight loss." | 7.78 | Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents. ( Blankson, KL; Cabrera, JL; Cole, RE; Symons, JE; Wilks, EG, 2012) |
| "Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin." | 7.78 | Sibutramine: a novel new agent for obesity treatment. ( Bray, GA; Kaiser, P; Ryan, DH, 1995) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 7.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| " We describe the case of a 46-year-old female patient presenting with a first episode of symptomatic porphyria after 10 d of sibutramine treatment for weight loss." | 7.76 | Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss. ( Eickmann, S; Finckh, U; Haverkamp, T; Reiser, M, 2010) |
| "In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population." | 7.76 | Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. ( Hsiao, TJ; Huang, SY; Hwang, Y; Lin, E; Wu, LS, 2010) |
| "Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans." | 7.76 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. ( Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M, 2010) |
| "It is well established that sibutramine produces weight loss and is used frequently in women of childbearing age." | 7.76 | Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats. ( Carnietto, N; Cicogna, AC; Fernandes, GS; Francia-Farje, LA; Kempinas, Wde G; Silva, DS; Volpato, GT, 2010) |
| "The relationship between weight reduction after sibutramine treatment and a single nucleotide polymorphism, rs5443 (C825T), in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene is currently inconsistent." | 7.75 | Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. ( Hsiao, DJ; Huang, SY; Lin, E; Wu, LS, 2009) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| " For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9." | 7.74 | Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008) |
| "This study was designed to examine whether prior authorization for insurer reimbursement of weight loss medication affects compliance with taking sibutramine or adherence to a medical weight control program." | 7.73 | Does prior authorization of sibutramine improve medication compliance or weight loss? ( Nieto, L; Risser, JA; Vash, PD, 2005) |
| "To study personality and clinical factors in weight loss by sibutramine (Meridia and Reductil), an anti-obesity drug enhancing satiety." | 7.72 | Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. ( Barkeling, B; Carlsson, AM; Elfhag, K; Rössner, S, 2003) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 7.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "To determine whether (1) patients who experience greater weight loss also experience correspondingly greater improvements in health-related quality of life (HRQOL); (2) the improvement in HRQOL is noticeable for patients achieving moderate (5%-10%) weight reduction; and (3) the relationship between weight reduction and HRQOL is similar for patients receiving sibutramine hydrochloride vs placebo." | 7.71 | Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. ( Kolotkin, RL; Mendel, CM; Nguyen, MH; Samsa, GP; Williams, GR, 2001) |
| "Sibutramine was well tolerated by most of the patients." | 6.69 | Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. ( Berber, A; Cuellar, GE; Monsalve, MC; Ruiz, AM, 2000) |
| "Although pharmacological treatment of obesity is widely used in most countries, the number of available drugs is still very limited." | 6.45 | The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ( Coutinho, W, 2009) |
| "Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor." | 6.41 | An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. ( Carruba, MO; Nisoli, E, 2000) |
| "Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease." | 6.41 | The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001) |
| "Sibutramine is an orally administered centrally acting weight management agent apparently devoid of amphetamine-like abuse potential." | 6.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| " Single dosing with sibutramine (3." | 5.35 | Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. ( Blundell, JE; Rodgers, RJ; Tallett, AJ, 2009) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 5.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 5.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 5.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "The CYP2B6*6 allele influences the extent of weight reduction and pulse rate changes in patients undergoing sibutramine treatment." | 5.19 | Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele. ( Ahn, HY; Hwang, IC; Kim, KA; Kim, KK; Ko, KD; Park, JY; Suh, HS, 2014) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| "The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise." | 5.19 | Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. ( Caterson, ID; Coutinho, W; Espinoza, D; Finer, N; Gebski, V; Ivers, L; James, WP; Legler, UF; Seimon, RV; Sharma, AM, 2014) |
| "To evaluate the effect of sibutramine on weight loss in obese adolescents." | 5.19 | [The effect of sibutramine on weight loss in obese adolescents]. ( Cominato, L; Damiani, D; Franco, RR, 2014) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 5.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 5.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine." | 5.16 | Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. ( Brooke, A; Delafont, B; Elkhawad, M; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Tan, CY; Vidal-Puig, A; Virtue, S, 2012) |
| "Body weight reduction was greater in the sibutramine group." | 5.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| " Therefore, we could not find any additional effects of Diacerein on weight loss and inflammatory variables in this study." | 5.15 | Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. ( Joo, NS; Kim, BT; Kim, CW; Kim, KM; Kim, SM; Lee, DJ, 2011) |
| "The aim of the present study was to compare the efficacy of 1 yr of sibutramine-induced weight loss versus continuous positive airway pressure (CPAP) treatment on sleep-disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnoea." | 5.14 | Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. ( Ferland, A; Poirier, P; Sériès, F, 2009) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 5.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| "We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants." | 5.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 5.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 5.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 5.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Obese patients have high plasma leptin concentrations that do not induce the expected responses on weight regulation, suggesting a leptin resistance in obesity." | 5.13 | Sympathetic-leptin relationship in obesity: effect of weight loss. ( Böhme, P; Quilliot, D; Zannad, F; Ziegler, O, 2008) |
| " We did not find any influence of 5% body weight loss induced by sibutramine on circulating levels of endocannabinoids and adipose-tissue expression of endocannabinoid genes in obese subjects." | 5.13 | Peripheral endocannabinoid system activity in patients treated with sibutramine. ( Bátkai, S; Engeli, S; Gorzelniak, K; Harvey-White, J; Heusser, K; Janke, J; Jordan, J; Luft, FC; Pacher, P, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women." | 5.12 | Influence of weight reduction by sibutramine on female sexual function. ( Kang, HC; Kim, KK; Kim, SS; Youn, BB, 2006) |
| "To describe our experience using sibutramine in weight reduction treatment of adolescents suffering from morbid obesity." | 5.12 | Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. ( Afriat, R; Bortnik, O; Goldman, M; Reisler, G; Tauber, T, 2006) |
| "In this randomized, double-blind, placebo-controlled study, the effect of sibutramine and cognitive-behavioural weight loss (cognitive-BWL) treatment was assessed in obese subjects with and without subclinical binge eating disorder (sBED)." | 5.12 | Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. ( Bauer, C; Fischer, A; Keller, U, 2006) |
| " Sibutramine, a serotonin and norepinephrine transporter blocker, is widely used as an adjunctive obesity treatment, but its impact on endothelial function in obese patients with CAD has not yet been investigated." | 5.12 | Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. ( Beigel, R; Feinberg, MS; Freimark, D; Matetzky, S; Shechter, M, 2006) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 5.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| "Open-label sibutramine treatment decreased body weight 4." | 5.12 | Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. ( Diedrich, A; Engeli, S; Heusser, K; Janke, J; Jordan, J; Luft, FC; Tank, J; Wiesner, S, 2007) |
| " The aim of this study was to test weight loss and impact on QoL after sibutramine treatment in obese subjects." | 5.12 | Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. ( Bissoli, L; Bosello, O; Cancelli, F; Di Francesco, V; Mazzali, G; Minniti, A; Sacco, T; Salanitri, T; Zamboni, M; Zoico, E, 2007) |
| "To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two." | 5.12 | Impact of weight loss on the metabolic syndrome. ( Berkowitz, RI; Cato, RK; Phelan, S; Rothman, R; Sarwer, DB; Wadden, TA; Womble, LG, 2007) |
| "Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype." | 5.12 | Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. ( Baxter, KL; Burton, DD; Camilleri, M; Clark, MM; Graszer, KM; Jensen, MD; Kalsy, SA; Tepoel, DA; Vazquez Roque, MI; Zinsmeister, AR, 2007) |
| "Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients." | 5.12 | Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. ( Apovian, CM; Aronne, LJ; Blakesley, V; Cwik, KM; Early, JL; Fernstrom, MH; Frank, A; Greenway, FL; Heber, D; Hewkin, AC; Kushner, RF; Walch, JK, 2007) |
| "Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy." | 5.12 | NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. ( Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S, 2007) |
| "Addition of low-dose metoprolol to sibutramine therapy increased patient compliance to the treatment, and decreased the frequency and severity of side effects including hypertension and palpitations, without decreasing the drug efficacy or causing significant deleterious changes in metabolic parameters." | 5.11 | Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. ( Baykan, M; Durmus, I; Erem, C; Ersoz, HO; Hacihasanoglu, A; Telatar, M; Ukinc, K, 2004) |
| "The mean weight loss was greater in the sibutramine group (-7." | 5.11 | Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. ( Kaukua, JK; Pekkarinen, TA; Rissanen, AM, 2004) |
| "To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index >or= 30 and < 40 kg/m(2)." | 5.11 | Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. ( Hauner, H; Kurscheid, T; Lauterbach, K; Meier, M; Wendland, G, 2004) |
| "Sibutramine of the dosage of 10 mg/day is an effective and safe therapy for weight reduction in obese subjects." | 5.11 | [A multicenter and open study on efficacy and safety of sibutramine in obese subjects]. ( Ning, G, 2004) |
| "Sibutramine and orlistat are currently used for weight loss." | 5.11 | Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. ( Altunbas, H; Balci, MK; Cakir, M; Karayalcin, U; Sari, R, 2004) |
| "In this population of obese Hispanic patients with type 2 diabetes, sibutramine combined with glibenclamide therapy achieved weight loss for up to 12 months and was associated with better glycemic control than placebo." | 5.11 | Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| "Both orlistat and sibutramine were effective on anthropometric variables and on metabolic pattern during the 12-month treatment; in our sample, orlistat appears to be slightly more efficacious as an anti-obesity drug, while sibutramine intake was not associated to any cardiovascular effect and was generally better tolerated than orlistat." | 5.11 | Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Murdolo, G, 2004) |
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 5.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| " Sibutramine and sibutramine in combination with orlistat seemed to be equally effective in terms of weight reduction compared to orlistat monotherapy." | 5.11 | Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. ( Aydin, N; Dağar, A; Ekmekcioglu, C; Filiz, M; Kaya, A; Kilinç, E; Oztürk, A; Topsever, P, 2004) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 5.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| "Sibutramine induced greater weight reduction than placebo (6." | 5.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 5.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "To assess the efficacy of sibutramine 15 mg once daily as weight reduction in overweight and obese (body mass index > 25 kg/m2) Chinese female type 2 diabetic patients and to evaluate the influence of weight loss on diabetic control, a randomised, double-blind, placebo-control, 12-week study was conducted." | 5.11 | Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. ( Chang, ET; Hsieh, MC; Kuo, SW; Li, JC; Pei, D; Su, KY; Tsai, CC; Tsai, WC; Wang, TF; Yao, CY, 2005) |
| "Weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months." | 5.11 | Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. ( Mathus-Vliegen, EM, 2005) |
| " The antiobesity agent sibutramine, unlike anorectic agents, decreases food intake mainly by stimulating satiety." | 5.11 | [Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents]. ( Appolinário, JC; Carraro, L; Corrêa, LL; Coutinho, WF; Faria Júnior, R; Godoy-Matos, AF; Meirelles, RM; Moreira, RO; Platt, MW; Póvoa, LC, 2005) |
| " Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss." | 5.10 | Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. ( Boivin, JM; Bruntz, JF; Drouin, P; Gille, B; Grentzinger, A; Hammadi, M; Hanotin, C; Igau, B; Zannad, F, 2002) |
| "To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program." | 5.10 | Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. ( Berkowitz, RI; Cronquist, JL; Tershakovec, AM; Wadden, TA, 2003) |
| "Seven adult subjects who had problems with binge eating (mean age, 42 years) were randomly assigned to receive alternating sibutramine and placebo in a double-blind placebo-controlled crossover study." | 5.10 | Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. ( Burgard, MA; Crosby, RD; de Zwaan, M; Gosnell, BA; Mitchell, JE; Roerig, JL; Wambach, BN; Wonderlich, SA, 2003) |
| "The objective of the study was to identify determinants of long-term success in weight maintenance in obese subjects who completed the Sibutramine Trial on Obesity Reduction and Maintenance (n = 261), a multicenter European study of weight loss and weight maintenance in obesity that combines sibutramine treatment with dietary restriction and advice on exercise and behavior." | 5.10 | Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). ( Astrup, AV; Finer, N; Hilsted, J; James, WP; Kopelman, PG; Rössner, S; Saris, WH; van Baak, MA; Van Gaal, LF; van Mil, E, 2003) |
| "To assess the effect of sibutramine-assisted weight reduction program on insulin sensitivity and metabolic parameters in obese normal glucose tolerant individuals over a period of 24 weeks." | 5.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 5.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 5.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 5.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "To investigate whether the satiety-inducing agent sibutramine affected body weight and associated anthropometry in overweight and obese (body mass index (BMI) > 27) Type 2 diabetic patients on sulphonylurea therapy." | 5.10 | Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. ( Melchionda, N; Moreno-Carretero, E; Serrano-Rios, M, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 5.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months." | 5.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "The aim of the present study was to evaluate the cerebrospinal fluid (CSF)/serum leptin ratio during pharmacological therapy for obesity with centrally and peripherally acting drugs." | 5.10 | The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. ( Boguszewski, CL; De Almeida, SM; Niclewicz, PA; Radominski, RB; Rodrigues, AM; Suplicy, Hde L, 2002) |
| " To illustrate how we may in the future be able to achieve longer-term weight maintenance, a brief outline of 1 study--the 2-year, randomized, double-blind, placebo-controlled study: Sibutramine Trial of Obesity Reduction and Maintenance--will be described." | 5.09 | Achieving weight-loss maintenance. ( James, WP, 2001) |
| "Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with 1 of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily." | 5.09 | Sibutramine produces dose-related weight loss. ( Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999) |
| "Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year." | 5.09 | Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. ( Apfelbaum, M; Hanotin, C; Leutenegger, E; Thomas, F; Vague, P; Ziegler, O, 1999) |
| "Sibutramine, an inhibitor of serotonin and noradrenaline uptake, reduces appetite to cause weight loss." | 5.09 | The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. ( Lean, ME; Leen, E; Walsh, KM, 1999) |
| "To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mg/d) vs placebo in obese subjects." | 5.09 | The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. ( Astrup, A; Hansen, DL; Macdonald, IA; Stock, MJ; Toubro, S, 1999) |
| "Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function." | 5.09 | A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000) |
| "To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b." | 5.09 | Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000) |
| ") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53." | 5.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| "Sibutramine 10 mg once daily is a useful, effective therapy for obesity in the presence of stable hypertension." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. ( Hazenberg, BP, 2000) |
| "In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects." | 5.09 | Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. ( Astrup, A; Finer, N; Goulder, M; Hansen, D; Hilsted, J; James, W; Kopelman, P; Rössner, S; Saris, W; Toubro, S; Van Gaal, L, 2001) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 5.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "Sibutramine is a tertiary amine that has been shown to induce dose-dependent weight loss and enhance the effects of a low-calorie diet for up to a year." | 5.09 | [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial]. ( Astrup, AV; Hansen, DL; Hilsted, JC; Porsborg, PA; Toubro, S, 2001) |
| "The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity." | 5.09 | Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001) |
| "To evaluate the insulin, leptin, and abdominal adiposity relation during weight loss in patients with upper body obesity." | 5.09 | Insulin-leptin-visceral fat relation during weight loss. ( DeShields, S; Elashoff, R; Go, VL; Heber, D; Hershman, JM; Liu, Y; Wang, HJ; Yip, I, 2001) |
| "In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels." | 5.09 | Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001) |
| "To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons." | 5.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "Sibutramine 10 mg once a day is an effective and safe therapy for weight reduction in simple over-weighted and obese subjects." | 5.09 | [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects]. ( Wang, X; Yan, Z; Zhao, Y, 2001) |
| "An open, non-comparative study was carried out to assess the efficacy and toleration profile of sibutramine, a new antiobesity drug, in promoting weight loss in obese type 2 diabetes mellitus subject who failed to reduce weight after strict dietary control." | 5.09 | Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management. ( Kumar, A; Lal, M; Sircar, AR, 2001) |
| "These data demonstrate dose-related weight loss with sibutramine treatment for up to 12 weeks in obese patients." | 5.08 | Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998) |
| "Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent." | 5.08 | Effects of sibutramine on resting metabolic rate and weight loss in overweight women. ( Bessesen, DH; Hill, JO; Seagle, HM, 1998) |
| " This paper examines the effect of sibutramine, a new serotonin and noradrenaline re-uptake inhibitor, on weight reduction and changes in fat distribution." | 5.08 | Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? ( De Leeuw, IH; Peiffer, FW; Van Gaal, LF; Wauters, MA, 1998) |
| " Carriers of leptin gene mutations are able to normalize their body weight after daily subcutaneous leptin administration." | 4.89 | Treatment options for children with monogenic forms of obesity. ( Hainerová, IA; Lebl, J, 2013) |
| "- changes in systolic and/or diastolic blood pressure - body weight reduction even though sibutramine and rimonabant have been withdrawn from the market." | 4.89 | Long-term effects of weight-reducing drugs in hypertensive patients. ( Berghold, A; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A; Siering, U, 2013) |
| " Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss." | 4.85 | Effect of antiobesity medications in patients with type 2 diabetes mellitus. ( Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET, 2009) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 4.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "Randomized controlled trials in adult hypertensive patients with a study duration of at least 24 weeks comparing pharmacologic interventions (orlistat, sibutramine, rimonabant) for weight loss with placebo." | 4.85 | Long-term effects of weight-reducing drugs in hypertensive patients. ( Berghold, A; Horvath, K; Jeitler, K; Matyas, E; Pignitter, N; Siebenhofer, A; Siering, U; Stich, AK, 2009) |
| "The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutramine for the short term on safety and efficacy for weight loss." | 4.84 | Sibutramine: current status as an anti-obesity drug and its future perspectives. ( Henderson, DC; Sharma, B, 2008) |
| " Two medications (sibutramine, orlistat) combined with behavioral interventions can result in small to moderate short-term weight loss in obese adolescents with potential side effects that range in severity." | 4.84 | Effectiveness of weight management programs in children and adolescents. ( Beil, T; Lutz, K; O'Connor, E; Whitlock, E; Williams, S, 2008) |
| " Sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4-5 kg, but is associated with increases in blood pressure and pulse rate." | 4.84 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. ( Majumdar, SR; Padwal, RS, 2007) |
| "This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine)." | 4.84 | Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. ( Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA, 2007) |
| "To investigate, through a meta-analysis of clinical trials, the effect of two weight-reducing drugs, such as orlistat and sibutramine, on serum lipid profiles in overweight and obese subjects, independently of weight loss." | 4.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| "Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively." | 4.83 | [Drug treatment of obesity]. ( Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S, 2006) |
| "We have re-analysed pooled data from seven randomized, controlled studies of sibutramine-induced weight loss and maintenance in which patients (n = 928; 75% female) had taken sibutramine 10 or 15 mg continuously for 12 months, in order to determine the predictors of success in weight loss (defined as loss of at least 5% of initial body weight at Month 12) in both diabetic and non-diabetic patients." | 4.83 | Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. ( Finer, N; Hewkin, AC; Renz, CL; Ryan, DH, 2006) |
| "Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity." | 4.83 | [Pharmacotherapy in the treatment of obesity]. ( Hamann, A, 2006) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| "This article describes the pharmacologic management of obesity, concentrating on orlistat and sibutramine." | 4.82 | Weight management and current options in pharmacotherapy: orlistat and sibutramine. ( Chan, JC; Leung, WY; Thomas, GN; Tomlinson, B, 2003) |
| "Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria." | 4.82 | Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2003) |
| " Evidence-based anti-obesity drugs such as sibutramine and orlistat facilitate the start of weight reduction, thus providing additional motivation of success, and support the long-term effect by stabilizing the weight loss." | 4.82 | [New therapeutic options in obesity]. ( Heufelder, AE, 2003) |
| " Currently approved pharmacologic treatments for obesity include sibutramine and orlistat, which have been associated with significantly greater weight loss than that seen with dieting alone." | 4.82 | Obesity and pharmacologic therapy. ( Aronne, LJ; Thearle, M, 2003) |
| " The summary mean differences in weight loss, sibutramine minus placebo, for the 3-month and 1-year trials were -2." | 4.82 | The efficacy and safety of sibutramine for weight loss: a systematic review. ( Arterburn, DE; Crane, PK; Veenstra, DL, 2004) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks." | 4.82 | Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. ( Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2004) |
| "Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria." | 4.82 | Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2004) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks." | 4.82 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| " In the United States, only sibutramine and orlistat are available for the long-term treatment of obesity." | 4.82 | Long-term pharmacotherapy for obesity. ( Klein, S, 2004) |
| "Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients." | 4.82 | A review of the metabolic effects of sibutramine. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome." | 4.81 | Metabolic benefits associated with sibutramine therapy. ( Krejs, GJ, 2002) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 4.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet." | 4.81 | The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002) |
| "Sibutramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which induces weight loss via a dual mode of action: enhancing both satiety and energy expenditure." | 4.80 | Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. ( De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998) |
| " The USA, the European Union and Norway have approved orlistat, a pancreatic lipase inhibitor for weight reduction for up to two years." | 4.80 | [The obesity epidemics--do diet pills have a place in the treatment?]. ( Birkeland, KI; Tonstad, S, 2000) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 4.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Sibutramine is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which causes weight loss in laboratory rodents via effects on both food intake and metabolic rate." | 4.79 | Sibutramine: a review of the pharmacology of a novel anti-obesity agent. ( Stock, MJ, 1997) |
| "Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day." | 4.79 | Sibutramine--a review of clinical efficacy. ( Lean, ME, 1997) |
| "Topiramate (alone or associated with sibutramine) and orlistat (alone or in combination) promoted significant weight loss after 2 years of use in patients submitted to bariatric surgery with weight regain." | 4.31 | Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study. ( Boger, BS; Canuto, MC; Cercato, C; de Melo, ME; Mancini, MC; Noriega, PEP; Queiroz, NL; Stumpf, MAM, 2023) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 3.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| "To determine the impact of FDA safety communications regarding the weight loss medications sibutramine and orlistat." | 3.80 | Time series analyses of the effect of FDA communications on use of prescription weight loss medications. ( Block, JP; Brennan, TA; Carpenter, DP; Choudhry, NK; Fischer, MA; Matlin, OS; Shrank, WH; Tong, AY, 2014) |
| "Despite a surprising decision of the European Drug Agency to suspend the registration of sibutramine in the whole of Europe since January 2010 we can state that in our patients we have proven a positive effect of sibutramine substitution on their weight reduction (Tab." | 3.79 | The role of sibutramine in weight reduction. ( Drahokoupilova, E; Fajfrova, J; Pavlik, V; Slovacek, L, 2013) |
| "Assess body mass index (BMI) reduction through a multidisciplinary intervention with sibutramine in adolescents of military parents and examine characteristics and behavioral traits as predictors of successful weight loss." | 3.78 | Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents. ( Blankson, KL; Cabrera, JL; Cole, RE; Symons, JE; Wilks, EG, 2012) |
| "Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin." | 3.78 | Sibutramine: a novel new agent for obesity treatment. ( Bray, GA; Kaiser, P; Ryan, DH, 1995) |
| "The health and longevity effects of body weight reduction resulting from exercise and caloric restriction in rodents are well known, but less is known about whether similar effects occur with weight reduction from the use of a pharmaceutical agent such as sibutramine, a serotonin-norepinephrine reuptake inhibitor." | 3.77 | No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. ( Allison, DB; Desmond, RA; Nagy, TR; Robertson, HT; Smith, DL, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension." | 3.77 | [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. ( Madsbad, S, 2011) |
| "Sibutramine is an anti-obesity agent that induces weight loss by selective inhibition of neuronal reuptake of serotonin and norepinephrine; however, it is associated with the risk of cardiovascular diseases (CVD), including heart attack and stroke." | 3.77 | Proteome changes in rat plasma in response to sibutramine. ( Choi, DK; Choi, JW; Joo, JI; Kim, DH; Oh, TS; Wang, X; Yun, JW, 2011) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 3.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| "In the management of obesity, using BIB together with sibutramine before the treatment in the patient group who are planned to have surgery, compared with using only BIB, provides more effective weight loss." | 3.76 | Assessment of the application of the intragastric balloon together with sibutramine: a prospective clinical study. ( Bostanci, O; Coskun, H, 2010) |
| " We describe the case of a 46-year-old female patient presenting with a first episode of symptomatic porphyria after 10 d of sibutramine treatment for weight loss." | 3.76 | Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss. ( Eickmann, S; Finckh, U; Haverkamp, T; Reiser, M, 2010) |
| "In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population." | 3.76 | Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. ( Hsiao, TJ; Huang, SY; Hwang, Y; Lin, E; Wu, LS, 2010) |
| "Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans." | 3.76 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. ( Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M, 2010) |
| "It is well established that sibutramine produces weight loss and is used frequently in women of childbearing age." | 3.76 | Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats. ( Carnietto, N; Cicogna, AC; Fernandes, GS; Francia-Farje, LA; Kempinas, Wde G; Silva, DS; Volpato, GT, 2010) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| "The relationship between weight reduction after sibutramine treatment and a single nucleotide polymorphism, rs5443 (C825T), in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene is currently inconsistent." | 3.75 | Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. ( Hsiao, DJ; Huang, SY; Lin, E; Wu, LS, 2009) |
| "We, therefore, conducted a study in which 20 bariatric patients received 15 mg of the weight loss medication sibutramine prior to laparoscopic Roux-en-Y gastric bypass (RYGBP) while patients in the control group did not." | 3.75 | Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. ( Aberle, J; Beil, FU; Busch, P; Dannheim, V; Freier, A; Mann, O; Mommsen, N, 2009) |
| "4 kg/m2) completed a 6-month weight loss intervention program by following either low calorie diet suggestions (LCDS; n=18), LCDS plus sibutramine (SG; n=27), LCDS plus orlistat (OG; n=41), or very low calorie diet (VLCD; n=33)." | 3.75 | What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese? ( Chang, CS; Kuo, HC; Wu, CH; Yu, C, 2009) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules." | 3.74 | Incorrect use of orlistat and sibutramine in clinical practice. ( Beermann, B; Dahlin, A, 2007) |
| "To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs." | 3.74 | Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. ( Elfhag, K; Finer, N; Rössner, S, 2008) |
| " For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9." | 3.74 | Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008) |
| "This study was designed to examine whether prior authorization for insurer reimbursement of weight loss medication affects compliance with taking sibutramine or adherence to a medical weight control program." | 3.73 | Does prior authorization of sibutramine improve medication compliance or weight loss? ( Nieto, L; Risser, JA; Vash, PD, 2005) |
| " The centrally acting antiobesity drug, sibutramine, was used as the reference comparator." | 3.73 | Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. ( Buschmann, H; Codony, X; Dordal, A; Fisas, A; Giraldo, J; Heal, D; Holenz, J; Mercé, R; Pauwels, PJ; Romero, G; Sørensen, RV; Vrang, N, 2006) |
| " A high serum folic acid level was the only independent predictor of weight loss at 1 year." | 3.73 | Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme. ( Candil, SD; Martínez, JJ; Ruiz, FA, 2006) |
| "The homozygosity/heterozygosity of the PNMT gene was highly predictive of significant weight loss with sibutramine during the first 3 months, which highlights the need for specific pharmacotherapy." | 3.72 | Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women. ( Comings, DE; Giese, RJ; MacMurry, JP; Peters, WR; Walker, J, 2003) |
| "To study personality and clinical factors in weight loss by sibutramine (Meridia and Reductil), an anti-obesity drug enhancing satiety." | 3.72 | Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. ( Barkeling, B; Carlsson, AM; Elfhag, K; Rössner, S, 2003) |
| "The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized." | 3.71 | [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine]. ( Scheen, AJ, 2001) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 3.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "To determine whether (1) patients who experience greater weight loss also experience correspondingly greater improvements in health-related quality of life (HRQOL); (2) the improvement in HRQOL is noticeable for patients achieving moderate (5%-10%) weight reduction; and (3) the relationship between weight reduction and HRQOL is similar for patients receiving sibutramine hydrochloride vs placebo." | 3.71 | Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. ( Kolotkin, RL; Mendel, CM; Nguyen, MH; Samsa, GP; Williams, GR, 2001) |
| "Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity." | 3.71 | [Pharma-clinics. Medication of the month. Sibutramine (Reductil)]. ( Scheen, AJ, 2001) |
| "Extent of weight loss was described successfully using a sigmoidal exposure-response relationship of the drug with a constant placebo effect in each individual." | 2.80 | Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development. ( Bae, SH; Han, S; Hong, T; Jang, DY; Jeon, S; Kim, KS; Lee, J; Park, GJ; Park, WS; Yim, DS; Youn, S, 2015) |
| "In obesity, left ventricular hypertrophy is frequently observed, especially in the presence of hypertension." | 2.72 | Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study. ( Boenner, G; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2006) |
| "Sibutramine is an anti-obesity agent." | 2.71 | Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. ( Cetinkaya, A; Guven, A; Koksal, N; Ozdemir, R; Sokmen, G, 2004) |
| "Sibutramine was well tolerated by most of the patients." | 2.69 | Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. ( Berber, A; Cuellar, GE; Monsalve, MC; Ruiz, AM, 2000) |
| "24 SD) with a high prevalence of gastrointestinal adverse effects." | 2.46 | Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. ( Hsia, Y; Tomsic, T; Viner, RM; Wong, IC, 2010) |
| "For sibutramine, higher on-treatment elevations in SBP (1." | 2.46 | Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. ( Johansson, K; Neovius, K; Neovius, M; Rössner, S; Sundström, J, 2010) |
| "Obesity is one of the greatest public health challenges of the twenty-first century." | 2.45 | Current pharmacotherapeutic concepts for the treatment of obesity in adults. ( Idelevich, E; Kirch, W; Schindler, C, 2009) |
| "Although pharmacological treatment of obesity is widely used in most countries, the number of available drugs is still very limited." | 2.45 | The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ( Coutinho, W, 2009) |
| "Obesity is epidemic; new medications and therapeutic options are urgently needed to reduce the associated health care burden." | 2.45 | What are the risks and the benefits of current and emerging weight-loss medications? ( Niswender, KD; Robinson, JR, 2009) |
| "Obesity is associated with an increased risk of developing several comorbid diseases, ranging from cardiovascular diseases to cholelithiasis and nonalcoholic fatty liver disease." | 2.44 | Obesity: a review of pathogenesis and management strategies. ( Kaila, B; Raman, M, 2008) |
| "Reduction of BP was higher in patients treated with weight loss diets (systolic BP [SBP]: weighted mean difference [WMD], -6." | 2.44 | Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. ( Gratzer, TW; Horvath, K; Jeitler, K; Siebenhofer, A; Siering, U; Skipka, G; Stich, AK, 2008) |
| "Obesity is a chronic disease requiring a similar long term approach to management as that of other chronic conditions." | 2.43 | Weight loss medications--where do they fit in? ( Dixon, JB, 2006) |
| "Obesity has been described as the greatest current threat to human health." | 2.43 | Current and novel approaches to the drug therapy of obesity. ( Chaput, JP; Tremblay, A, 2006) |
| "In recent years, obesity has become a major public health problem in Western countries." | 2.43 | Medical strategies for weight loss in the overweight and obese patient. ( Bonanomi, G; Di Caro, S; Fernstrom, MH; Hamad, GG; Schauer, PR, 2006) |
| "Obesity infrequently associated with type 2 diabetes mellitus and may cause insulin resistance, hypertension and other complications of obesity." | 2.42 | Obesity management in patients with type 2 diabetes mellitus. ( Mannan, MA; Rahman, MS; Siddiqui, NI, 2004) |
| "Obesity is a chronic medical disorder that is not going away anytime soon." | 2.42 | What role for weight-loss medication? Weighing the pros and cons for obese patients. ( Hill, JO; Wyatt, HR, 2004) |
| "Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management." | 2.42 | Clinical use of sibutramine. ( Ryan, DH, 2004) |
| "Obesity is the most important modifiable risk factor for type 2 diabetes mellitus and most patients with diabetes are overweight or obese." | 2.42 | Managing type 2 diabetes mellitus in patients with obesity. ( Hauner, H, 2004) |
| "Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor." | 2.41 | An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. ( Carruba, MO; Nisoli, E, 2000) |
| "Obesity has now been identified as a chronic disease, a global epidemic (globesity) and a serious public health issue that leads to reduced life expectancy, an increased risk for many serious medical conditions and enormous healthcare costs." | 2.41 | Sibutramine lost and found. ( Bosello, O; Carruba, MO; Ferrannini, E; Rotella, CM, 2002) |
| "Sibutramine has a dual mode of action." | 2.41 | Sibutramine: its mode of action and efficacy. ( Finer, N, 2002) |
| "Sibutramine has actions on both energy intake and expenditure and had been shown to enhance weight loss and weight maintenance achieved by diet, in simple obesity as well as when accompanied by complications of diabetes or hypertension." | 2.41 | Pharmacotherapy of obesity. ( Finer, N, 2002) |
| "Obesity is a growing public health problem worldwide." | 2.41 | Obesity: a rational target for managing diabetes mellitus. ( Mooradian, AD, 2001) |
| "Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease." | 2.41 | The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001) |
| "Obesity is characterised by pathophysiological defects affecting both sides of the energy balance equation." | 2.40 | What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. ( Astrup, A; Lundsgaard, C, 1998) |
| "Sibutramine is an orally administered centrally acting weight management agent apparently devoid of amphetamine-like abuse potential." | 2.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| "Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease." | 2.40 | Obesity and type 2 diabetes: a conflict of interests? ( Williams, G, 1999) |
| " A multifaceted approach to the obese patient should include identifying potential causes for weight gain, outlining medical conditions that would benefit by weight loss, and tailoring a weight loss program that is safe and effective for the individual." | 2.40 | Safe and effective management of the obese patient. ( Collazo-Clavell, ML, 1999) |
| " We analyzed toxic and trace element levels of nine herbal products and found that these herbal products, even in low amounts, contain Pb, Al, Ni, and Ba." | 1.39 | How safe is the use of herbal weight-loss products sold over the internet? ( Celbis, O; Erdogan, S; Kapucu, H; Karakoc, Y; Onal, Y; Ozdemir, B; Sahin, I, 2013) |
| "Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication." | 1.38 | Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. ( Cheung, BM; Leung, RY; Ong, KL; Samaranayake, NR, 2012) |
| " The model could also be used to assess dose-response relationships." | 1.38 | Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model. ( Chan, LS; Kaptein, EM; Kaptein, JS, 2012) |
| "Long-term pharmacologic treatments for weight loss maintenance have been studied and were found to have modest success, with some weight regain typically reported." | 1.36 | Weight loss maintenance. ( Grief, SN; Miranda, RL, 2010) |
| "Sibutramine is a centrally acting serotonin/noradrenaline reuptake inhibitor that mainly increases satiety." | 1.35 | [Pharmacological therapy of obesity]. ( Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008) |
| "A 39-year-old white woman started to take sibutramine to lose weight at a dosage of 10 mg/day." | 1.35 | Sibutramine-associated psychosis (case report). ( Gazdag, G; Szabó, Z, 2008) |
| "Obesity is a major health problem in the United States and many other countries because of its high prevalence and causal relationship with serious medical comorbidities." | 1.35 | Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. ( Fabbrini, E; Klein, S, 2008) |
| " Single dosing with sibutramine (3." | 1.35 | Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. ( Blundell, JE; Rodgers, RJ; Tallett, AJ, 2009) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 1.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| "The orlistat-treated group had a mean weight loss of 2." | 1.32 | Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. ( Al Daghri, N; Barnett, AH; Chetty, R; Field, A; Hanif, W; Kumar, S; McTernan, PG; Valsamakis, G, 2004) |
| "Obesity is a chronic condition with complex, multiple causes involving physiologic, genetic, and behavioral components, all of which must be addressed for successful treatment." | 1.31 | Treating obesity in the family practice setting. ( Fernstrom, MH, 2001) |
| "Obesity is a significant health problem in the United States today and is associated with increased risk of cardiovascular disease, diabetes, and other chronic conditions." | 1.31 | Emerging strategies for weight management. Summary. ( Hansen, BC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (7.46) | 18.2507 |
| 2000's | 213 (72.20) | 29.6817 |
| 2010's | 58 (19.66) | 24.3611 |
| 2020's | 2 (0.68) | 2.80 |
| Authors | Studies |
|---|---|
| Semple, G | 1 |
| Tran, TA | 1 |
| Kramer, B | 1 |
| Hsu, D | 1 |
| Han, S | 2 |
| Choi, J | 1 |
| Vallar, P | 1 |
| Casper, MD | 1 |
| Zou, N | 1 |
| Hauser, EK | 1 |
| Thomsen, W | 1 |
| Whelan, K | 1 |
| Sengupta, D | 1 |
| Morgan, M | 1 |
| Sekiguchi, Y | 1 |
| Kanuma, K | 1 |
| Chaki, S | 1 |
| Grottick, AJ | 1 |
| Xiang, H | 1 |
| Zhao, W | 1 |
| Xiao, H | 1 |
| Qian, L | 1 |
| Yao, Y | 1 |
| Li, XB | 1 |
| Liao, QJ | 1 |
| Waseem, R | 1 |
| Raza, M | 1 |
| Aftab, A | 1 |
| Boger, BS | 1 |
| Queiroz, NL | 1 |
| Noriega, PEP | 1 |
| Canuto, MC | 1 |
| Stumpf, MAM | 1 |
| Cercato, C | 1 |
| Mancini, MC | 2 |
| de Melo, ME | 1 |
| Shin, HY | 1 |
| Park, S | 1 |
| Lee, JW | 2 |
| Dedov, II | 1 |
| Melnichenko, GA | 1 |
| Troshina, EA | 1 |
| Mazurina, NV | 1 |
| Galieva, MO | 1 |
| Pavlik, V | 2 |
| Fajfrova, J | 1 |
| Slovacek, L | 2 |
| Drahokoupilova, E | 1 |
| Hainerová, IA | 1 |
| Lebl, J | 1 |
| Siebenhofer, A | 4 |
| Jeitler, K | 4 |
| Horvath, K | 4 |
| Berghold, A | 3 |
| Siering, U | 3 |
| Semlitsch, T | 2 |
| Mans, DJ | 1 |
| Gucinski, AC | 1 |
| Dunn, JD | 1 |
| Gryniewicz-Ruzicka, CM | 1 |
| Mecker-Pogue, LC | 1 |
| Kao, JL | 1 |
| Ge, X | 1 |
| Trigueros, L | 1 |
| Peña, S | 1 |
| Ugidos, AV | 1 |
| Sayas-Barberá, E | 1 |
| Pérez-Álvarez, JA | 1 |
| Sendra, E | 1 |
| Block, JP | 1 |
| Choudhry, NK | 1 |
| Carpenter, DP | 1 |
| Fischer, MA | 1 |
| Brennan, TA | 1 |
| Tong, AY | 1 |
| Matlin, OS | 1 |
| Shrank, WH | 1 |
| Hwang, IC | 3 |
| Park, JY | 1 |
| Ahn, HY | 2 |
| Kim, KK | 4 |
| Suh, HS | 3 |
| Ko, KD | 2 |
| Kim, KA | 1 |
| Suplicy, H | 1 |
| Boguszewski, CL | 2 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Bertholee, D | 1 |
| ter Horst, PG | 1 |
| Wieringa, A | 1 |
| Smit, JP | 1 |
| Seimon, RV | 2 |
| Espinoza, D | 2 |
| Ivers, L | 1 |
| Gebski, V | 2 |
| Finer, N | 15 |
| Legler, UF | 3 |
| Sharma, AM | 7 |
| James, WP | 8 |
| Coutinho, W | 8 |
| Caterson, ID | 7 |
| Warner, JV | 1 |
| Morton, AP | 1 |
| Hall, AJ | 1 |
| Henman, MG | 1 |
| Pool, LF | 1 |
| Franco, RR | 1 |
| Cominato, L | 1 |
| Damiani, D | 1 |
| Gur'yanova, NN | 1 |
| Bugaeva, LI | 2 |
| Lebedeva, SA | 2 |
| Tekutova, TV | 1 |
| Dugina, YL | 1 |
| Petrov, VI | 2 |
| Epshtein, OI | 1 |
| Van Gaal, L | 5 |
| Maggioni, AP | 4 |
| Sweeting, A | 1 |
| Torp-Pedersen, C | 7 |
| Douglas, IJ | 1 |
| Bhaskaran, K | 1 |
| Batterham, RL | 1 |
| Smeeth, L | 1 |
| Jeon, S | 1 |
| Hong, T | 1 |
| Lee, J | 1 |
| Bae, SH | 1 |
| Park, WS | 1 |
| Park, GJ | 1 |
| Youn, S | 1 |
| Jang, DY | 1 |
| Kim, KS | 1 |
| Yim, DS | 1 |
| Posch, N | 1 |
| Meschik, J | 1 |
| Kamil, S | 1 |
| James, WPT | 1 |
| Andersson, C | 2 |
| Sharma, B | 1 |
| Henderson, DC | 1 |
| Bacher, HP | 1 |
| Shepherd, GM | 3 |
| Slovackova, B | 1 |
| Coskun, H | 1 |
| Bostanci, O | 1 |
| Grudell, AB | 1 |
| Sweetser, S | 1 |
| Camilleri, M | 2 |
| Eckert, DJ | 1 |
| Vazquez-Roque, MI | 1 |
| Carlson, PJ | 1 |
| Burton, DD | 2 |
| Braddock, AE | 1 |
| Clark, MM | 2 |
| Graszer, KM | 2 |
| Kalsy, SA | 2 |
| Zinsmeister, AR | 2 |
| Pagotto, U | 1 |
| Vanuzzo, D | 1 |
| Vicennati, V | 1 |
| Pasquali, R | 1 |
| Mercer, SW | 1 |
| Lean, ME | 3 |
| Gazdag, G | 1 |
| Szabó, Z | 1 |
| Fabbrini, E | 1 |
| Klein, S | 2 |
| Tallett, AJ | 1 |
| Blundell, JE | 1 |
| Rodgers, RJ | 1 |
| Idelevich, E | 1 |
| Kirch, W | 1 |
| Schindler, C | 1 |
| Faulconbridge, LF | 1 |
| Wadden, TA | 10 |
| Berkowitz, RI | 8 |
| Sarwer, DB | 6 |
| Womble, LG | 5 |
| Hesson, LA | 2 |
| Stunkard, AJ | 2 |
| Fabricatore, AN | 2 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Digenio, AG | 1 |
| Mancuso, JP | 1 |
| Gerber, RA | 1 |
| Dvorak, RV | 1 |
| Choussein, S | 1 |
| Makri, AA | 1 |
| Frangos, CC | 1 |
| Petridou, ET | 1 |
| Daskalopoulou, SS | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 1 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Ferland, A | 1 |
| Poirier, P | 1 |
| Sériès, F | 1 |
| Georgopoulos, NA | 2 |
| Katsikis, I | 5 |
| Florakis, D | 2 |
| Panidis, D | 5 |
| Kandarakis, ED | 1 |
| Whitlock, E | 1 |
| O'Connor, E | 1 |
| Williams, S | 1 |
| Beil, T | 1 |
| Lutz, K | 1 |
| Weeke, P | 1 |
| Fosbøl, EL | 1 |
| Brendorp, B | 1 |
| Køber, L | 1 |
| Rode, RA | 2 |
| Tziomalos, K | 3 |
| Krassas, GE | 1 |
| Tzotzas, T | 1 |
| Moore, RH | 1 |
| Butryn, ML | 1 |
| Heymsfield, SB | 3 |
| Nguyen, AM | 1 |
| Czernichow, S | 1 |
| Lee, CM | 1 |
| Barzi, F | 1 |
| Greenfield, JR | 1 |
| Baur, LA | 1 |
| Chalmers, J | 1 |
| Woodward, M | 1 |
| Huxley, RR | 1 |
| Stich, AK | 2 |
| Matyas, E | 1 |
| Pignitter, N | 1 |
| Fernstrom, MH | 5 |
| Hansen, BC | 1 |
| Hsiao, DJ | 1 |
| Wu, LS | 2 |
| Huang, SY | 2 |
| Lin, E | 2 |
| Aberle, J | 1 |
| Freier, A | 1 |
| Busch, P | 1 |
| Mommsen, N | 1 |
| Beil, FU | 1 |
| Dannheim, V | 1 |
| Mann, O | 1 |
| Krishna, R | 1 |
| Gumbiner, B | 1 |
| Stevens, C | 1 |
| Musser, B | 2 |
| Mallick, M | 2 |
| Suryawanshi, S | 1 |
| Maganti, L | 1 |
| Zhu, H | 1 |
| Han, TH | 1 |
| Scherer, L | 1 |
| Simpson, B | 1 |
| Cosgrove, D | 1 |
| Gottesdiener, K | 1 |
| Amatruda, J | 1 |
| Rolls, BJ | 2 |
| Blundell, J | 1 |
| Bray, GA | 3 |
| Fujioka, K | 5 |
| Wagner, JA | 1 |
| Herman, GA | 1 |
| Van Gaal, LF | 7 |
| Ge, H | 1 |
| Moran, SA | 1 |
| Wu, CH | 2 |
| Kuo, HC | 1 |
| Chang, CS | 1 |
| Yu, C | 1 |
| Robinson, JR | 1 |
| Niswender, KD | 1 |
| Reiser, M | 1 |
| Eickmann, S | 1 |
| Haverkamp, T | 1 |
| Finckh, U | 1 |
| Viner, RM | 1 |
| Hsia, Y | 1 |
| Tomsic, T | 1 |
| Wong, IC | 1 |
| Sari, R | 2 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 1 |
| Phillips, CL | 2 |
| Yee, BJ | 2 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 2 |
| Berend, N | 1 |
| Grunstein, RR | 2 |
| Johansson, K | 2 |
| Sundström, J | 1 |
| Neovius, K | 1 |
| Rössner, S | 7 |
| Neovius, M | 2 |
| Aronne, LJ | 4 |
| Halseth, AE | 1 |
| Burns, CM | 1 |
| Miller, S | 1 |
| Shen, LZ | 1 |
| Kaplan, LM | 1 |
| Hsiao, TJ | 1 |
| Hwang, Y | 1 |
| Hansen, HH | 1 |
| Hansen, G | 1 |
| Tang-Christensen, M | 1 |
| Larsen, PJ | 1 |
| Axel, AM | 1 |
| Raben, A | 1 |
| Mikkelsen, JD | 1 |
| Francia-Farje, LA | 1 |
| Silva, DS | 1 |
| Volpato, GT | 1 |
| Fernandes, GS | 1 |
| Carnietto, N | 1 |
| Cicogna, AC | 1 |
| Kempinas, Wde G | 1 |
| Astrup, A | 6 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Drazen, JM | 1 |
| Grief, SN | 1 |
| Miranda, RL | 1 |
| Smith, DL | 1 |
| Robertson, HT | 1 |
| Desmond, RA | 1 |
| Nagy, TR | 1 |
| Allison, DB | 1 |
| Joo, NS | 1 |
| Kim, SM | 1 |
| Kim, KM | 1 |
| Kim, CW | 1 |
| Kim, BT | 1 |
| Lee, DJ | 1 |
| Koiou, E | 2 |
| Dinas, K | 1 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Madsbad, S | 1 |
| Choi, JW | 1 |
| Joo, JI | 1 |
| Kim, DH | 1 |
| Wang, X | 2 |
| Oh, TS | 1 |
| Choi, DK | 1 |
| Yun, JW | 1 |
| Vosnakis, C | 2 |
| Farina, MG | 1 |
| Baratta, R | 1 |
| Nigro, A | 1 |
| Vinciguerra, F | 1 |
| Puglisi, C | 1 |
| Schembri, R | 1 |
| Virgilio, C | 1 |
| Vigneri, R | 1 |
| Frittitta, L | 1 |
| Hemo, B | 1 |
| Endevelt, R | 1 |
| Porath, A | 1 |
| Stampfer, MJ | 1 |
| Shai, I | 1 |
| Papazoglou, D | 1 |
| Restas, E | 1 |
| Papanas, N | 1 |
| Papatheodorou, K | 1 |
| Babouris, C | 1 |
| Glaros, D | 1 |
| Antonoglou, C | 1 |
| Maltezos, E | 1 |
| Abo-Elmatty, DM | 1 |
| Zaitone, SA | 1 |
| Perdok, RJ | 1 |
| Renz, CL | 3 |
| Gray, LJ | 1 |
| Cooper, N | 1 |
| Dunkley, A | 1 |
| Warren, FC | 1 |
| Ara, R | 2 |
| Abrams, K | 1 |
| Davies, MJ | 1 |
| Khunti, K | 1 |
| Sutton, A | 1 |
| Samaranayake, NR | 1 |
| Ong, KL | 1 |
| Leung, RY | 1 |
| Cheung, BM | 1 |
| Napolitano, A | 1 |
| Miller, SR | 1 |
| Murgatroyd, PR | 1 |
| Delafont, B | 1 |
| Brooke, A | 1 |
| Elkhawad, M | 1 |
| Tan, CY | 1 |
| Virtue, S | 1 |
| Vidal-Puig, A | 1 |
| Nunez, DJ | 1 |
| Ozdemir, B | 1 |
| Sahin, I | 1 |
| Kapucu, H | 1 |
| Celbis, O | 1 |
| Karakoc, Y | 1 |
| Erdogan, S | 1 |
| Onal, Y | 1 |
| Hiatt, WR | 1 |
| Thomas, A | 1 |
| Goldfine, AB | 1 |
| Cabrera, JL | 1 |
| Wilks, EG | 1 |
| Symons, JE | 1 |
| Blankson, KL | 1 |
| Cole, RE | 1 |
| Armeni, AK | 1 |
| Papadakis, E | 1 |
| Roupas, ND | 1 |
| Kheyfets, IA | 1 |
| Vorob'eva, TM | 1 |
| Dugina, JL | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Kaptein, EM | 1 |
| Chan, LS | 1 |
| Kaptein, JS | 1 |
| Oh, SW | 1 |
| Nisoli, E | 1 |
| Carruba, MO | 2 |
| Matiba, B | 3 |
| Zannad, F | 2 |
| Gille, B | 1 |
| Grentzinger, A | 1 |
| Bruntz, JF | 1 |
| Hammadi, M | 1 |
| Boivin, JM | 1 |
| Hanotin, C | 3 |
| Igau, B | 1 |
| Drouin, P | 2 |
| Binkley, K | 1 |
| Knowles, SR | 1 |
| Bosello, O | 2 |
| Ferrannini, E | 1 |
| Rotella, CM | 2 |
| Krejs, GJ | 1 |
| Fernstrom, JD | 2 |
| Scheen, AJ | 3 |
| Ernest, P | 1 |
| Gura, T | 1 |
| Peters, WR | 1 |
| MacMurry, JP | 1 |
| Walker, J | 1 |
| Giese, RJ | 1 |
| Comings, DE | 1 |
| Leung, WY | 1 |
| Thomas, GN | 1 |
| Chan, JC | 1 |
| Tomlinson, B | 1 |
| Lee, TH | 1 |
| Tershakovec, AM | 1 |
| Cronquist, JL | 1 |
| Mitchell, JE | 1 |
| Gosnell, BA | 1 |
| Roerig, JL | 1 |
| de Zwaan, M | 1 |
| Wonderlich, SA | 1 |
| Crosby, RD | 1 |
| Burgard, MA | 1 |
| Wambach, BN | 1 |
| Whisenhunt, BL | 1 |
| Williamson, DA | 1 |
| Netemeyer, RG | 1 |
| Andrews, C | 1 |
| van Baak, MA | 1 |
| van Mil, E | 1 |
| Astrup, AV | 3 |
| Hilsted, J | 2 |
| Kopelman, PG | 1 |
| Saris, WH | 1 |
| Tambascia, MA | 1 |
| Geloneze, B | 1 |
| Repetto, EM | 1 |
| Geloneze, SR | 1 |
| Picolo, M | 1 |
| Magro, DO | 1 |
| Sabuncu, T | 1 |
| Nazligul, Y | 1 |
| Karaoglanoglu, M | 1 |
| Ucar, E | 1 |
| Kilic, FB | 1 |
| Connor, H | 1 |
| Annan, F | 1 |
| Bunn, E | 1 |
| Frost, G | 2 |
| McGough, N | 1 |
| Sarwar, T | 1 |
| Thomas, B | 1 |
| Padwal, R | 2 |
| Li, SK | 2 |
| Lau, DC | 2 |
| Engeli, S | 3 |
| Clark, VL | 1 |
| Foster, GD | 1 |
| Elfhag, K | 3 |
| Carlsson, AM | 1 |
| Barkeling, B | 2 |
| Heufelder, AE | 1 |
| Guven, A | 1 |
| Koksal, N | 1 |
| Cetinkaya, A | 1 |
| Sokmen, G | 1 |
| Ozdemir, R | 1 |
| Thearle, M | 1 |
| Ersoz, HO | 1 |
| Ukinc, K | 1 |
| Baykan, M | 1 |
| Erem, C | 1 |
| Durmus, I | 1 |
| Hacihasanoglu, A | 1 |
| Telatar, M | 1 |
| Mannan, MA | 1 |
| Rahman, MS | 1 |
| Siddiqui, NI | 1 |
| Wyatt, HR | 1 |
| Hill, JO | 2 |
| Kaukua, JK | 1 |
| Pekkarinen, TA | 1 |
| Rissanen, AM | 1 |
| Ryan, DH | 5 |
| Valsamakis, G | 1 |
| McTernan, PG | 1 |
| Chetty, R | 1 |
| Al Daghri, N | 1 |
| Field, A | 1 |
| Hanif, W | 1 |
| Barnett, AH | 1 |
| Kumar, S | 1 |
| Hauner, H | 2 |
| Meier, M | 1 |
| Wendland, G | 1 |
| Kurscheid, T | 1 |
| Lauterbach, K | 1 |
| Arterburn, DE | 1 |
| Crane, PK | 1 |
| Veenstra, DL | 1 |
| Norris, SL | 2 |
| Zhang, X | 2 |
| Avenell, A | 2 |
| Gregg, E | 2 |
| Schmid, CH | 2 |
| Kim, C | 1 |
| Lau, J | 2 |
| Ning, G | 1 |
| Balci, MK | 1 |
| Cakir, M | 1 |
| Altunbas, H | 1 |
| Karayalcin, U | 1 |
| Sánchez-Reyes, L | 3 |
| Fanghänel, G | 3 |
| Yamamoto, J | 1 |
| Martínez-Rivas, L | 1 |
| Campos-Franco, E | 1 |
| Berber, A | 5 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Künnecke, B | 1 |
| Verry, P | 1 |
| Bénardeau, A | 1 |
| von Kienlin, M | 1 |
| Svendsen, OL | 3 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| Murdolo, G | 1 |
| Ciccarelli, L | 1 |
| Fogari, R | 1 |
| Hainer, V | 1 |
| Kunesova, M | 1 |
| Bellisle, F | 1 |
| Hill, M | 1 |
| Braunerova, R | 1 |
| Wagenknecht, M | 1 |
| Kaya, A | 1 |
| Aydin, N | 1 |
| Topsever, P | 1 |
| Filiz, M | 1 |
| Oztürk, A | 1 |
| Dağar, A | 1 |
| Kilinç, E | 1 |
| Ekmekcioglu, C | 1 |
| Mersebach, H | 1 |
| Klose, M | 1 |
| Feldt-Rasmussen, U | 1 |
| Rooth, P | 1 |
| Risser, JA | 1 |
| Vash, PD | 1 |
| Nieto, L | 1 |
| Faria, AN | 2 |
| Ribeiro Filho, FF | 2 |
| Kohlmann, NE | 1 |
| Gouvea Ferreira, SR | 1 |
| Zanella, MT | 2 |
| Filippatos, TD | 2 |
| Kiortsis, DN | 2 |
| Liberopoulos, EN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 2 |
| de Simone, G | 2 |
| Romano, C | 1 |
| De Caprio, C | 1 |
| Contaldo, F | 1 |
| Salanitri, T | 2 |
| di Luzio Paparatti, U | 1 |
| Pasanisi, F | 1 |
| Redmon, JB | 1 |
| Reck, KP | 1 |
| Raatz, SK | 1 |
| Swanson, JE | 1 |
| Kwong, CA | 1 |
| Ji, H | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Wang, TF | 1 |
| Pei, D | 1 |
| Li, JC | 1 |
| Tsai, WC | 1 |
| Tsai, CC | 1 |
| Yao, CY | 1 |
| Chang, ET | 1 |
| Hsieh, MC | 1 |
| Su, KY | 1 |
| Kuo, SW | 1 |
| Mathus-Vliegen, EM | 1 |
| Corrêa, LL | 1 |
| Platt, MW | 1 |
| Carraro, L | 1 |
| Moreira, RO | 1 |
| Faria Júnior, R | 1 |
| Godoy-Matos, AF | 1 |
| Meirelles, RM | 1 |
| Póvoa, LC | 1 |
| Appolinário, JC | 1 |
| Coutinho, WF | 2 |
| Halford, JC | 1 |
| Phelan, S | 3 |
| Cato, RK | 2 |
| Osei, SY | 1 |
| Kaplan, R | 1 |
| Yanovski, SZ | 1 |
| Toubro, S | 6 |
| Breum, L | 1 |
| Bruun, JM | 1 |
| Kang, HC | 1 |
| Kim, SS | 1 |
| Youn, BB | 1 |
| Hewkin, AC | 3 |
| Reisler, G | 1 |
| Tauber, T | 1 |
| Afriat, R | 1 |
| Bortnik, O | 1 |
| Goldman, M | 1 |
| Letonturier, P | 1 |
| Clark, JM | 1 |
| Hamann, A | 1 |
| Bauer, C | 1 |
| Fischer, A | 1 |
| Keller, U | 1 |
| Caterson, I | 2 |
| Hedner, JA | 1 |
| Shechter, M | 1 |
| Beigel, R | 1 |
| Freimark, D | 1 |
| Matetzky, S | 1 |
| Feinberg, MS | 1 |
| Halpern, A | 1 |
| Fisas, A | 1 |
| Codony, X | 1 |
| Romero, G | 1 |
| Dordal, A | 1 |
| Giraldo, J | 1 |
| Mercé, R | 1 |
| Holenz, J | 1 |
| Vrang, N | 1 |
| Sørensen, RV | 1 |
| Heal, D | 1 |
| Buschmann, H | 1 |
| Pauwels, PJ | 1 |
| Daniels, SR | 1 |
| Hoppin, AG | 1 |
| Owen, S | 1 |
| Perry, AC | 1 |
| Sothern, MS | 1 |
| Pirner, MA | 1 |
| Walch, JK | 2 |
| Jasinsky, O | 1 |
| Blakesley, VA | 1 |
| Dietz, WH | 1 |
| García-Morales, LM | 1 |
| Macias-Lara, CC | 1 |
| Lucio-Ortiz, C | 1 |
| Del-Rio-Navarro, BE | 1 |
| Dorantes-Alvárez, LM | 1 |
| Dixon, JB | 1 |
| Pi-Sunyer, FX | 1 |
| Chaput, JP | 1 |
| Tremblay, A | 1 |
| Lundquist, LM | 1 |
| Sirimaturos, M | 1 |
| Cannon, E | 1 |
| Wirth, A | 2 |
| Scholze, J | 1 |
| Boenner, G | 1 |
| Brennan, A | 1 |
| Sterz, R | 1 |
| Bergemann, R | 1 |
| Martínez, JJ | 1 |
| Ruiz, FA | 1 |
| Candil, SD | 1 |
| Di Caro, S | 1 |
| Hamad, GG | 1 |
| Schauer, PR | 1 |
| Bonanomi, G | 1 |
| Dahlin, A | 1 |
| Beermann, B | 1 |
| Padwal, RS | 1 |
| Majumdar, SR | 1 |
| Gursoy, A | 1 |
| Erdogan, MF | 1 |
| Cin, MO | 1 |
| Cesur, M | 1 |
| Baskal, N | 1 |
| Heusser, K | 2 |
| Tank, J | 1 |
| Diedrich, A | 1 |
| Wiesner, S | 1 |
| Janke, J | 2 |
| Luft, FC | 2 |
| Jordan, J | 2 |
| Di Francesco, V | 1 |
| Sacco, T | 1 |
| Zamboni, M | 1 |
| Bissoli, L | 1 |
| Zoico, E | 1 |
| Mazzali, G | 1 |
| Minniti, A | 1 |
| Cancelli, F | 1 |
| Rothman, R | 1 |
| Vazquez Roque, MI | 1 |
| Tepoel, DA | 1 |
| Jensen, MD | 1 |
| Baxter, KL | 1 |
| Yuen, YP | 1 |
| Lai, CK | 1 |
| Poon, WT | 1 |
| Ng, SW | 1 |
| Chan, AY | 1 |
| Mak, TW | 1 |
| Early, JL | 1 |
| Apovian, CM | 2 |
| Frank, A | 1 |
| Greenway, FL | 2 |
| Heber, D | 2 |
| Kushner, RF | 1 |
| Cwik, KM | 1 |
| Blakesley, V | 1 |
| Tsouli, S | 1 |
| Konitsiotis, S | 1 |
| Maggioni, A | 1 |
| Sharma, A | 1 |
| Brisco, W | 1 |
| Deaton, R | 1 |
| Shepherd, G | 1 |
| James, P | 1 |
| Lindholm, Å | 1 |
| Bixo, M | 1 |
| Björn, I | 1 |
| Wölner-Hanssen, P | 1 |
| Eliasson, M | 1 |
| Larsson, A | 1 |
| Johnson, O | 1 |
| Poromaa, IS | 1 |
| Liou, TH | 1 |
| Chien, HC | 1 |
| Lin, WY | 1 |
| Lee, WJ | 1 |
| Chou, P | 1 |
| Erondu, N | 1 |
| Addy, C | 1 |
| Lu, K | 1 |
| Gantz, I | 1 |
| Proietto, J | 1 |
| Rissannen, AM | 1 |
| Tonstad, S | 2 |
| Haynes, WG | 1 |
| Gottesdiener, KM | 1 |
| Kaufman, KD | 1 |
| Amatruda, JM | 1 |
| Rubio, MA | 1 |
| Gargallo, M | 1 |
| Isabel Millán, A | 1 |
| Moreno, B | 1 |
| Franz, MJ | 1 |
| VanWormer, JJ | 1 |
| Crain, AL | 1 |
| Boucher, JL | 1 |
| Histon, T | 1 |
| Caplan, W | 1 |
| Bowman, JD | 1 |
| Pronk, NP | 1 |
| Mannucci, E | 1 |
| Dicembrini, I | 1 |
| Rotella, F | 1 |
| Choi, S | 1 |
| Suter, PM | 1 |
| Kolyvanos, NU | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| von Haehling, S | 1 |
| Lainscak, M | 1 |
| Anker, SD | 1 |
| Diamanti-Kandarakis, E | 1 |
| Nassis, GP | 1 |
| Karkanaki, A | 1 |
| Georgopoulos, N | 1 |
| Bönner, G | 1 |
| Bahadori, B | 1 |
| Uitz, E | 1 |
| Tonninger-Bahadori, K | 1 |
| Moghadasian, MH | 1 |
| Kaila, B | 1 |
| Raman, M | 1 |
| Nau, JY | 1 |
| Rotstein, A | 1 |
| Inbar, O | 1 |
| Vaisman, N | 1 |
| Quilliot, D | 1 |
| Böhme, P | 1 |
| Ziegler, O | 2 |
| Gorzelniak, K | 1 |
| Bátkai, S | 1 |
| Pacher, P | 1 |
| Harvey-White, J | 1 |
| Skipka, G | 1 |
| Gratzer, TW | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Bischoff, A | 1 |
| Barratt, R | 1 |
| O'Boyle, A | 1 |
| Millward, J | 1 |
| Truby, H | 1 |
| Lee, HR | 1 |
| Shim, JY | 1 |
| Im, JA | 1 |
| Lee, DC | 1 |
| D'Addeo, G | 1 |
| Kaiser, P | 1 |
| Stock, MJ | 2 |
| Thomas, F | 2 |
| Jones, SP | 1 |
| Leutenegger, E | 2 |
| Shide, DJ | 1 |
| Thorwart, ML | 1 |
| Ulbrecht, JS | 1 |
| Seagle, HM | 1 |
| Bessesen, DH | 1 |
| Wauters, MA | 2 |
| Peiffer, FW | 3 |
| De Leeuw, IH | 3 |
| Rissanen, A | 1 |
| Lundsgaard, C | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| Blackburn, GL | 2 |
| Ferguson, JM | 1 |
| Jain, AK | 1 |
| Mendel, CM | 4 |
| Mendels, J | 1 |
| Schwartz, SL | 1 |
| Scheinbaum, ML | 1 |
| Seaton, TB | 2 |
| Apfelbaum, M | 1 |
| Vague, P | 1 |
| Maughan, KL | 1 |
| Williams, G | 1 |
| Walsh, KM | 1 |
| Leen, E | 1 |
| Hansen, DL | 2 |
| Macdonald, IA | 1 |
| Collazo-Clavell, ML | 1 |
| Cuellar, GE | 1 |
| Ruiz, AM | 1 |
| Monsalve, MC | 1 |
| Cortinas, L | 2 |
| Kunt, T | 1 |
| Birkeland, KI | 1 |
| Trakas, K | 1 |
| Leiter, L | 1 |
| Shear, NH | 1 |
| Prus-Wisniewski, R | 1 |
| Steinberg, C | 1 |
| Keipes, M | 1 |
| Fuente Martinez, M | 1 |
| Nicolay, L | 1 |
| Kuffer, V | 1 |
| Mersch, L | 1 |
| Klees, J | 1 |
| Jacqué, M | 1 |
| Bloom, SR | 1 |
| Frost, GS | 1 |
| Banks, LM | 1 |
| Griffiths, J | 1 |
| Rowe, E | 3 |
| Jelinek, CA | 1 |
| Raskin, P | 1 |
| Lebovitz, HE | 1 |
| Weinstein, SP | 3 |
| Hazenberg, BP | 1 |
| Hansen, D | 1 |
| Kopelman, P | 1 |
| Saris, W | 1 |
| James, W | 1 |
| Goulder, M | 1 |
| Després, JP | 1 |
| Hilsted, JC | 1 |
| Porsborg, PA | 1 |
| Smith, IG | 1 |
| Goulder, MA | 1 |
| Heine, RJ | 1 |
| McLaughlin, T | 2 |
| Abbasi, F | 2 |
| Kim, HS | 2 |
| Lamendola, C | 2 |
| Schaaf, P | 1 |
| Reaven, G | 1 |
| Reaven, GM | 1 |
| Yip, I | 1 |
| Go, VL | 1 |
| Hershman, JM | 1 |
| Wang, HJ | 1 |
| Elashoff, R | 1 |
| DeShields, S | 1 |
| Liu, Y | 1 |
| Dujovne, CA | 1 |
| Zavoral, JH | 1 |
| Mooradian, AD | 1 |
| Krause, J | 1 |
| Samsa, GP | 1 |
| Kolotkin, RL | 1 |
| Williams, GR | 1 |
| Nguyen, MH | 1 |
| Fontaine, KR | 1 |
| Rothman, RA | 1 |
| Gokcel, A | 2 |
| Karakose, H | 2 |
| Ertorer, EM | 1 |
| Tanaci, N | 2 |
| Tutuncu, NB | 1 |
| Guvener, N | 2 |
| Jakicic, JM | 1 |
| Clark, K | 1 |
| Coleman, E | 1 |
| Donnelly, JE | 1 |
| Foreyt, J | 1 |
| Melanson, E | 1 |
| Volek, J | 1 |
| Volpe, SL | 1 |
| Stevenson, JH | 1 |
| Trojian, T | 1 |
| Jackson, EA | 1 |
| Zhao, Y | 1 |
| Yan, Z | 1 |
| Eisenberg, D | 1 |
| Sircar, AR | 1 |
| Kumar, A | 1 |
| Lal, M | 1 |
| Sramek, JJ | 1 |
| Leibowitz, MT | 1 |
| Rowe, ED | 1 |
| Levy, B | 1 |
| McMahon, FG | 2 |
| Mullican, WS | 1 |
| Toth, PD | 1 |
| Cutler, NR | 1 |
| Ernst, KR | 1 |
| Johnson, F | 1 |
| Serrano-Rios, M | 1 |
| Melchionda, N | 1 |
| Moreno-Carretero, E | 1 |
| Gumurdulu, Y | 1 |
| Melek Ertorer, E | 1 |
| BascilTutuncu, N | 1 |
| Lerario, DD | 1 |
| Kohlmann, N | 1 |
| Ferreira, SR | 1 |
| Rodrigues, AM | 1 |
| Radominski, RB | 1 |
| Suplicy, Hde L | 1 |
| De Almeida, SM | 1 |
| Niclewicz, PA | 1 |
| Mustajoki, P | 1 |
| Luque, CA | 1 |
| Rey, JA | 1 |
| Verspohl, EJ | 1 |
| Francis, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine[NCT01184560] | 174 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832] | Phase 3 | 10,777 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients[NCT00433641] | Phase 4 | 181 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea[NCT00729963] | Phase 4 | 45 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [NCT00482638] | Phase 2 | 0 participants | Interventional | 2004-05-12 | Completed | ||
| [NCT00482196] | Phase 2 | 173 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| The Efficacy and Safety of Electro-acupuncture for Abdominal Obesity: Original Study for a Multicenter, Randomized, Sham-controlled Trial[NCT04957134] | 66 participants (Actual) | Interventional | 2021-07-22 | Completed | |||
| Time Restricted Eating as a Treatment for Pediatric Obesity[NCT05124847] | 30 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| Weight Loss & Maintenance of Weight Loss Tracking Study (SUCCESS Tracking Study)[NCT01021917] | 332 participants (Anticipated) | Observational | 2008-03-31 | Terminated (stopped due to Given the length of time data was collected (i.e. 5 1/3 years), we do not anticipate a change any potential conclusions by completing the final survey.) | |||
| The Effect of Metabolism-Boosting Beverages on 24 Hr Energy Expenditure[NCT01029236] | 30 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance[NCT01011491] | 90 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults[NCT01803737] | 26 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease[NCT03354247] | 100 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents[NCT00261911] | Phase 3 | 498 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| A Study to Assess the Compliance and Impact on Weight of Kurbo, a Pediatric Centered Weight Loss App[NCT02880254] | 27 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain[NCT02199483] | 0 participants (Actual) | Observational | 2014-07-21 | Withdrawn | |||
| Progressive Weight Loss and Metabolic Health[NCT01299519] | 59 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Eat Well for Life: A Weight Loss Maintenance Study[NCT01849627] | 345 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 418 |
| Randomized Placebo | 404 |
For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 200 |
| Randomized Placebo | 159 |
For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 127 |
| Randomized Placebo | 95 |
This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 927 |
| Randomized Placebo | 856 |
For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 11 |
| Randomized Placebo | 7 |
For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 223 |
| Randomized Placebo | 229 |
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Intent-to-treat population | |
| CV + DM Randomized to Placebo | 346 |
| CV + DM Randomized to Sibutramine | 403 |
| CV Only Randomized to Placebo | 66 |
| CV Only Randomized to Sibutramine | 77 |
| DM Only Randomized to Placebo | 77 |
| DM Only Randomized to Sibutramine | 79 |
| Randomized Placebo | 490 |
| Randomized Sibutramine | 561 |
Body weight will be measured on a digital scale to assess change in body weight over the 12-week intervention period. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kg (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -5.6 |
| Campaign Intervention (CI) | -3.1 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of carbohydrate intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.64 |
| Campaign Intervention (CI) | 0.90 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of fat intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -3.26 |
| Campaign Intervention (CI) | -0.00 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of protein intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.73 |
| Campaign Intervention (CI) | 0.44 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/day (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 474.8 |
| Campaign Intervention (CI) | 242.5 |
A questionnaire will be used to measure and quantify energy expenditure from physical activity. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/wk (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 983.3 |
| Campaign Intervention (CI) | 776.3 |
Self-efficacy for weight loss was assessed at week 0 and 12 using a 20-item Weight Efficacy Lifestyle Questionnaire (WEL). The total score ranges from 0-180. Higher values represent greater beliefs toward the completion of weight management behaviors. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 28.3 |
| Campaign Intervention (CI) | 16.3 |
The frequency that participants engaged in the self-monitoring of dietary intake and physical activity was assessed at week 12. The diaries were completed weekly throughout the study. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of diaries completed (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 91.6 |
| Campaign Intervention (CI) | 60.1 |
At week 12, participants completed the 13-item TSRQ to assess motivation to continue to participate in the program if given the opportunity. The TSRQ represents participants' reasons for continuing participation in a weight loss program via participants' endorsement of statements of autonomous and controlled motivation. Responses were given using a 7-point Likert scale (1 = not at all true to 7 = very true). The responses on the autonomous items (5) and controlled items (8) were averaged. (NCT01803737)
Timeframe: Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Autonomous Motivation | Controlled Motivation | |
| Campaign Intervention (CI) | 5.3 | 2.9 |
| Standard Behavioral Weight Loss Intervention (SBWL) | 6.3 | 2.9 |
BMI zscore will be determined from mathematical calculations derived from subject's height and weight. Z score is the number of standard deviations from the mean. A Z score of 0 is the mean. A change in z score in the positive direction reflects an increase in BMI Z score. A change in z score in the negative direction reflects a decrease in BMI Z score. A decrease in BMI z score indicates a change in BMI that favors weight loss. (NCT02880254)
Timeframe: 3 months
| Intervention | z score (Mean) |
|---|---|
| Kurbo Only | 2.4 |
| Kurbo Plus PHC | 2.2 |
"A questionnaire will be handed out to each subject every month (see below) where applicable.we will utilize one-sample tests with a one-sided alpha of 0.025. One-sided tests will be used as we are only interested in whether the use of this app results in better outcomes than usual care. Compliance will utilize a binomial probability test to assess compliance against our known compliance of 50%.~Questionnaire is noted here:~Confidential Page 1 of 1 Kurbo Survey [baseline_arm_1][name], DOB [baseline_arm_1][dob] Please complete the survey below. Thank you! Group Allocation __________________________________ Who is completing this survey? Child / Patient Parent / Guardian Over the last month, abou" (NCT02880254)
Timeframe: 3 months
| Intervention | percent compliant (Number) | |
|---|---|---|
| compliance with food tracking | compliance with exercise tracking | |
| Kurbo Only | 0 | 0 |
| Kurbo Plus PHC | 14 | 7 |
80 reviews available for sibutramine and Weight Loss
| Article | Year |
|---|---|
Treatment options for children with monogenic forms of obesity.
Topics: Bariatric Surgery; Body Mass Index; Body Weight; Child; Cyclobutanes; Energy Metabolism; Heterozygot | 2013 |
Long-term effects of weight-reducing drugs in hypertensive patients.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Humans; Hypertensi | 2013 |
Food ingredients as anti-obesity agents: a review.
Topics: Anti-Obesity Agents; Calcium, Dietary; Cyclobutanes; Diet; Dietary Fiber; Energy Metabolism; Exercis | 2013 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Fema | 2016 |
Sibutramine: current status as an anti-obesity drug and its future perspectives.
Topics: Adult; Appetite Depressants; Cyclobutanes; Humans; Obesity; Weight Loss | 2008 |
Current pharmacotherapeutic concepts for the treatment of obesity in adults.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme In | 2009 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabe | 2009 |
Effectiveness of weight management programs in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Child; C | 2008 |
The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes | 2009 |
The use of sibutramine in the management of obesity and related disorders: an update.
Topics: Adult; Appetite Depressants; Biomarkers; Blood Glucose; Cardiovascular Diseases; Child; Cyclobutanes | 2009 |
Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Lipids; Ob | 2010 |
Long-term effects of weight-reducing drugs in hypertensive patients.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Female; Humans; Hypertension; Lactones; Ma | 2009 |
What are the risks and the benefits of current and emerging weight-loss medications?
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2009 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactone | 2010 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; | 2012 |
An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
Topics: Anti-Obesity Agents; Biogenic Monoamines; Cyclobutanes; Eating; Energy Metabolism; Humans; Obesity; | 2000 |
Sibutramine lost and found.
Topics: Antidepressive Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Italy; Obesity; Quality o | 2002 |
Sibutramine: its mode of action and efficacy.
Topics: Appetite Depressants; Cyclobutanes; Energy Metabolism; Humans; Obesity; Prognosis; Weight Loss | 2002 |
Metabolic benefits associated with sibutramine therapy.
Topics: Adipose Tissue; Appetite Depressants; Cyclobutanes; Diabetes Mellitus; Humans; Lipids; Obesity; Weig | 2002 |
Pharmacotherapy of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; History, 20th Ce | 2002 |
The new role of pharmacotherapy for weight reduction in obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orli | 2002 |
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Clinical Trials as Topic; Controlled Clini | 2002 |
Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Dose-Response Relationship, Drug; Drug Interacti | 2003 |
Long-term pharmacotherapy for obesity and overweight.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl | 2003 |
[New therapeutic options in obesity].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobu | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity management in patients with type 2 diabetes mellitus.
Topics: Cyclobutanes; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Gastric Bypass; Humans; Obesity; We | 2004 |
What role for weight-loss medication? Weighing the pros and cons for obese patients.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orli | 2004 |
Clinical use of sibutramine.
Topics: Chronic Disease; Clinical Trials as Topic; Contraindications; Cyclobutanes; Female; Humans; Hyperten | 2004 |
The efficacy and safety of sibutramine for weight loss: a systematic review.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Heart Rate; Humans; Obesity; Randomized Controll | 2004 |
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Dru | 2004 |
Long-term pharmacotherapy for obesity and overweight.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin | 2005 |
Long-term pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Random | 2004 |
A review of the metabolic effects of sibutramine.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated | 2005 |
Managing type 2 diabetes mellitus in patients with obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; D | 2004 |
Pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cost of Illness; Cyclobutanes; Feeding Behavior; Humans; | 2006 |
[Drug treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; | 2006 |
Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diabetes | 2006 |
Weight loss as a treatment for nonalcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Chronic Disease; Cyclobutanes; Diet, R | 2006 |
[Pharmacotherapy in the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topi | 2006 |
Pharmacological treatment of obesity.
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Ene | 2006 |
Weight loss medications--where do they fit in?
Topics: Anti-Obesity Agents; Chronic Disease; Cyclobutanes; Diethylpropion; Humans; Lactones; Obesity; Orlis | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Current and novel approaches to the drug therapy of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Models, Biological; Obesi | 2006 |
Pharmacologic treatment for obesity. Options for today...and tomorrow.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lact | 2006 |
Medical strategies for weight loss in the overweight and obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Cyclobutanes; Exercise | 2006 |
Metabolic syndrome treatment strategies.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; O | 2006 |
Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Ob | 2007 |
Therapeutic options for modifying cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hypoglycem | 2007 |
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyr | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Orlistat and sibutramine beyond weight loss.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hyp | 2008 |
The development of tolerance to drugs that suppress food intake.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Huma | 2008 |
[Obesity in adults].
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobut | 2007 |
Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.
Topics: Anti-Obesity Agents; Cyclobutanes; Female; Humans; Lactones; Male; Obesity; Orlistat; Randomized Con | 2008 |
Obesity: a review of pathogenesis and management strategies.
Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary | 2008 |
Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Hypertension; Lactones; Obesity; Orlista | 2008 |
Sibutramine: a novel new agent for obesity treatment.
Topics: Adolescent; Adult; Aged; Animals; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle A | 1995 |
Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Antidepressive Agents; Body Temperature Regulat | 1997 |
Sibutramine--a review of clinical efficacy.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physio | 1997 |
Pharmacological intervention: the antiobesity approach.
Topics: Appetite Depressants; Blood Glucose; Controlled Clinical Trials as Topic; Cyclobutanes; Dexfenfluram | 1998 |
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Topics: Adrenergic beta-Agonists; Animals; Appetite Depressants; Caffeine; Central Nervous System Stimulants | 1998 |
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
Topics: Adipose Tissue; Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Dexfenfluramine; | 1998 |
Sibutramine. A review of its contribution to the management of obesity.
Topics: Animals; Appetite Depressants; Controlled Clinical Trials as Topic; Cyclobutanes; Energy Intake; Fem | 1998 |
Obesity and type 2 diabetes: a conflict of interests?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; | 1999 |
Safe and effective management of the obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Cognitive Behavioral Therapy; Cyclobutanes; Exercise; Gas | 1999 |
The use of pharmacologic agents in the treatment of the obese patient.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; Humans; Lactones; Mal | 1999 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obe | 2000 |
Does drug therapy of obesity have a future?
Topics: Animals; Appetite Depressants; Cyclobutanes; Humans; Leptin; Mice; Mice, Obese; Obesity; Weight Loss | 2000 |
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluram | 2000 |
Obesity: a rational target for managing diabetes mellitus.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
The importance of obesity in diabetes and its treatment with sibutramine.
Topics: Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Obesity; | 2001 |
The discovery and status of sibutramine as an anti-obesity drug.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobuta | 2002 |
Combining behavioral and pharmacological treatments for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes | 2002 |
[Weight reduction. Antiobesity drug treatment in type-2 diabetics].
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diabetes | 2002 |
109 trials available for sibutramine and Weight Loss
| Article | Year |
|---|---|
Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Female; | 2018 |
Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
Topics: Adolescent; Adult; Alleles; Cyclobutanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochr | 2014 |
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2014 |
Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Double-Blind Method; Drug Therapy, C | 2014 |
[The effect of sibutramine on weight loss in obese adolescents].
Topics: Adolescent; Appetite Depressants; Blood Glucose; Body Mass Index; Child; Cholesterol; Cross-Over Stu | 2014 |
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabetic Angiopa | 2015 |
Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development.
Topics: Adult; Anti-Obesity Agents; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Middle Aged; No | 2015 |
Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.
Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Diet; Dose-Response Relationsh | 2017 |
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2009 |
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
Topics: Adult; Appetite Depressants; Body Composition; Cyclobutanes; Feeding Behavior; Female; Gastric Empty | 2008 |
Changes in symptoms of depression with weight loss: results of a randomized trial.
Topics: Adult; Affect; Appetite Depressants; Behavior Control; Behavior Therapy; Cyclobutanes; Depression; F | 2009 |
Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial.
Topics: Adult; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Counseling; Cyclobutanes; | 2009 |
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Continuous Positive Airway Pressure; C | 2009 |
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi | 2009 |
Predictors of attrition and weight loss success: Results from a randomized controlled trial.
Topics: Adult; Age Factors; Appetite Depressants; Body Weight; Combined Modality Therapy; Cyclobutanes; Depr | 2009 |
Achieving weight-loss maintenance.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Composition; Body Mass Index; Confidence Interva | 2001 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Topics: Adolescent; Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Drug Therapy, Combination; Fe | 2010 |
Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.
Topics: Absorptiometry, Photon; Adiponectin; Adult; Anthraquinones; Anti-Inflammatory Agents; Appetite Depre | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity.
Topics: Adolescent; Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Female; Gastric Ba | 2012 |
Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine.
Topics: Alleles; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Female; | 2012 |
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind | 2012 |
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.
Topics: Absorptiometry, Photon; Adult; Appetite Depressants; Body Composition; Body Weight; Calorimetry, Ind | 2012 |
Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
Topics: Adult; Anthropometry; Anti-Mullerian Hormone; Appetite Depressants; Caloric Restriction; Cyclobutane | 2012 |
Effect of the G-protein β3 subunit 825T allele on the change of body adiposity in obese female.
Topics: Adiposity; Adult; Alleles; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Drug Synergism; | 2013 |
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Double | 2002 |
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Biomarkers; Blood Pressure; Body Mass Index; Com | 2003 |
Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm.
Topics: Adult; Appetite Depressants; Bulimia; Cross-Over Studies; Cyclobutanes; Double-Blind Method; Eating; | 2003 |
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).
Topics: Adolescent; Adult; Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Europe; Female; Humans; Leisu | 2003 |
Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Cyclobutanes; Double-Blind Method; Fe | 2003 |
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Fema | 2003 |
Great expectations: "I'm losing 25% of my weight no matter what you say".
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Female; Follow-Up Studies; Hum | 2003 |
Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
Topics: Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Echocardiography; Female; Follow-Up Studi | 2004 |
Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Anthropometry; Appetite Depressants; Arrhythmias, Cardiac; Cyclo | 2004 |
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Complications; Diabetes Mel | 2004 |
Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Female; Heart Rate; Huma | 2004 |
[A multicenter and open study on efficacy and safety of sibutramine in obese subjects].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; H | 2004 |
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Lact | 2004 |
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Bl | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Topics: Anthropometry; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double- | 2004 |
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cognitive Behavioral Therapy; Combin | 2005 |
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Drug Therapy, Combination; Female; Follow-Up S | 2004 |
Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood.
Topics: Adult; Affect; Cyclobutanes; Depression; Feeding Behavior; Female; Humans; Male; Middle Aged; Obesit | 2005 |
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Chi-Square Distribution; Cyclobutanes; Drug Th | 2005 |
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobu | 2005 |
Two-year outcome of a combination of weight loss therapies for type 2 diabetes.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diabete | 2005 |
Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; F | 2005 |
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Exerc | 2005 |
[Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents].
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Obesity; | 2005 |
Randomized trial of lifestyle modification and pharmacotherapy for obesity.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Combined Modality Therapy; Counseling; Cyclobu | 2005 |
Influence of weight reduction by sibutramine on female sexual function.
Topics: Adult; Antidepressive Agents; Appetite Depressants; Behavior Therapy; Body Composition; Combined Mod | 2006 |
Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity.
Topics: Adolescent; Appetite Depressants; Chemotherapy, Adjuvant; Cyclobutanes; Diet, Reducing; Female; Huma | 2006 |
Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Bulimia; Cognitive Behavioral Therapy; Combined Modal | 2006 |
Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease.
Topics: Aged; Appetite Depressants; Brachial Artery; Coronary Disease; Cyclobutanes; Endothelium, Vascular; | 2006 |
Effects of sibutramine treatment in obese adolescents: a randomized trial.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Blood Pressure; Body Height; Body Mass Index; Ch | 2006 |
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Mexico; O | 2006 |
Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
Topics: Adult; Appetite Depressants; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Composition | 2006 |
Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Red | 2006 |
Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Body Weight; Cyclobutanes; Female; Hum | 2007 |
Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Topics: Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Double-Blind Method; Female; Humans; Mal | 2007 |
Impact of weight loss on the metabolic syndrome.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Female; Humans; Life Style; Male; Metabolic Syndrom | 2007 |
Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Chromatography, High Pressure Liquid | 2007 |
Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
Topics: Adolescent; Adult; Algorithms; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cy | 2007 |
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Topics: Adult; Affect; Analysis of Variance; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyc | 2008 |
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
Topics: Aged; Appetite Depressants; Cyclobutanes; Diabetic Angiopathies; Double-Blind Method; Female; Humans | 2007 |
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Appetite Depressants; Body Weight; Cardiovascular Diseases; Cyclobutanes; Double- | 2008 |
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug | 2007 |
The obese older female patient: CV risk and the SCOUT study.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2007 |
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut | 2008 |
The effect of sibutramine intake on resting and exercise physiological responses.
Topics: Adult; Analysis of Variance; Appetite Depressants; Basal Metabolism; Body Mass Index; Cyclobutanes; | 2008 |
Sympathetic-leptin relationship in obesity: effect of weight loss.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Cyclobutanes; Female; Heart Rate; Hum | 2008 |
Peripheral endocannabinoid system activity in patients treated with sibutramine.
Topics: Abdominal Fat; Adolescent; Adult; Appetite Depressants; Arachidonic Acids; Biopsy; Body Weight; Cann | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
Sibutramine: a novel new agent for obesity treatment.
Topics: Adolescent; Adult; Aged; Animals; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle A | 1995 |
Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Topics: Adult; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 1998 |
Sibutramine reduces food intake in non-dieting women with obesity.
Topics: Appetite Depressants; Cross-Over Studies; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Dietary | 1998 |
Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
Topics: Adolescent; Adult; Appetite Depressants; Basal Metabolism; Blood Pressure; Body Composition; Cyclobu | 1998 |
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?
Topics: Adipose Tissue; Adult; Body Composition; Body Constitution; Cyclobutanes; Double-Blind Method; Femal | 1998 |
Sibutramine produces dose-related weight loss.
Topics: Adult; Appetite Depressants; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclob | 1999 |
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Femal | 1999 |
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females.
Topics: Adult; Appetite Depressants; Basal Metabolism; Body Temperature Regulation; Cardiac Output; Cyclobut | 1999 |
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Calorimetry, Indirect; Cyclobutanes; | 1999 |
Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Constitution; Body Mass Index; Cardiovascular Sy | 2000 |
A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Topics: Administration, Oral; Adolescent; Adult; Aged; Appetite Depressants; Body Constitution; Body Mass In | 2000 |
Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise Thera | 2001 |
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Gluco | 2000 |
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Diabet | 2000 |
Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Cyclobutanes; Diastole; Double-Blin | 2000 |
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Fe | 2001 |
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Topics: Adolescent; Adult; Aged; Anthropometry; Appetite Depressants; Body Mass Index; Body Weight; Cross-Ov | 2001 |
[The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Diet, Reducing; Double-Blind Method; Fem | 2001 |
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Topics: Adult; Aged; Appetite Depressants; Behavior Therapy; Body Mass Index; Body Weight; Combined Modality | 2001 |
Insulin-leptin-visceral fat relation during weight loss.
Topics: Adipose Tissue; Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insulin; | 2001 |
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Weight; Cyclobutanes; Double-Blind Method; Femal | 2001 |
Long-term weight loss with sibutramine: a randomized controlled trial.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Bli | 2001 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Ma | 2001 |
Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Do | 2001 |
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Appetite Depressants; Benzothiadiazines; Blood Pressure; C | 2002 |
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Appetite Depressants; Benzothiadiazines; Blood Pres | 2002 |
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cholesterol; Cyclobutanes; Diabetes Mellitus; Di | 2002 |
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo | 2002 |
Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
Topics: Antihypertensive Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Dr | 2002 |
The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity.
Topics: Adolescent; Adult; Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; La | 2002 |
107 other studies available for sibutramine and Weight Loss
| Article | Year |
|---|---|
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Cyclohexylamines; Eating; Humans; Male; Pyrimidi | 2009 |
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Obesity Agents; Cell Differentiation; Cell Line; Esters; Fat | 2010 |
Accentuating cardiovascular events in Sibutramine-treated patients.
Topics: Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Humans; Weight Loss | 2021 |
Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study.
Topics: Aged; Anti-Obesity Agents; Bariatric Surgery; Female; Humans; Male; Middle Aged; Obesity, Morbid; Or | 2023 |
Positive association between the changes in chemerin and adiponectin levels after weight reduction.
Topics: Adiponectin; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Body Mass Index; Chemokin | 2017 |
The role of sibutramine in weight reduction.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity; Weight | 2013 |
Rapid screening and structural elucidation of a novel sibutramine analogue in a weight loss supplement: 11-desisobutyl-11-benzylsibutramine.
Topics: Chromatography, Liquid; Cyclobutanes; Dietary Supplements; Magnetic Resonance Spectroscopy; Tandem M | 2013 |
Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Cyclobutanes; Dr | 2014 |
[Life-threatening psychosis caused by using sibutramine-contaminated weight-loss coffee].
Topics: Adult; Appetite Depressants; Brazil; Coffee; Cyclobutanes; Female; Food Contamination; Humans; Inter | 2013 |
Internet slimming, thyrotoxicosis and the liver.
Topics: Adult; Appetite Depressants; Chemical and Drug Induced Liver Injury; China; Cyclobutanes; Drug Combi | 2014 |
Experimental study of the efficiency of Dietressa preparation on body weight reduction in mice feeding high-fat ration.
Topics: Animals; Anti-Obesity Agents; Antibodies; Appetite Depressants; Cannabinoid Receptor Antagonists; Cy | 2014 |
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Case-Control Studies; Cyclobutane | 2015 |
The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Topics: Antidepressive Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Depression; Humans; Long | 2008 |
Assessment of the application of the intragastric balloon together with sibutramine: a prospective clinical study.
Topics: Adult; Appetite Depressants; Body Mass Index; Combined Modality Therapy; Cyclobutanes; Female; Gastr | 2010 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagon | 2008 |
Request for slimming tablets.
Topics: Adult; Appetite Depressants; Cyclobutanes; Family Practice; Female; Humans; Medical History Taking; | 2008 |
Sibutramine-associated psychosis (case report).
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Humans; Psychotic Disorders; Risk Factors; Stress | 2008 |
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cy | 2008 |
Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
Topics: Animals; Anorexia; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Fee | 2009 |
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Female; Humans; Insulin Resistance | 2009 |
Treating obesity in the family practice setting.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; H | 2001 |
Exploring synergies in the treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Combined Modality Ther | 2001 |
Emerging strategies for weight management. Summary.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Feeding Behavior; Health B | 2001 |
Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cyclobutanes; Female | 2009 |
Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time.
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Gastric Bypass; Humans; Liver; Male; Obesity, Mor | 2009 |
What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese?
Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutane | 2009 |
Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss.
Topics: Appetite Depressants; Cyclobutanes; Female; Flavoproteins; Genetic Predisposition to Disease; Humans | 2010 |
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.
Topics: Adipose Tissue; Adult; Body Composition; Cyclobutanes; Demography; Female; Humans; Ion Channels; Mal | 2010 |
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Topics: Adipose Tissue; Animals; Appetite; Biogenic Monoamines; Blood Glucose; Bridged Bicyclo Compounds, He | 2010 |
Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats.
Topics: Animals; Appetite Depressants; Cyclobutanes; Embryo Loss; Female; Overweight; Pregnancy; Rats; Rats, | 2010 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Hum | 2010 |
Sibutramine--another flawed diet pill.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Myocardial Infarction; Obesity; | 2010 |
Weight loss maintenance.
Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Reducing; Exercise; Gastric Bypass; Humans; Lactones; Obesi | 2010 |
No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.
Topics: Animals; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Longevity; Mi | 2011 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobuta | 2011 |
Proteome changes in rat plasma in response to sibutramine.
Topics: Adipose Tissue; Animals; Appetite Depressants; Appetite Regulation; Blood Proteins; Body Weight; Car | 2011 |
Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Body Mass Index; Comorbidity; Cyclobutanes; Diabet | 2011 |
Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Cyclobutanes; Female; Fructose; Insulin | 2011 |
Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008.
Topics: Adult; Anti-Obesity Agents; Cyclobutanes; Exercise; Female; Humans; Life Style; Male; Middle Aged; N | 2012 |
How safe is the use of herbal weight-loss products sold over the internet?
Topics: Anti-Obesity Agents; Caffeine; Cyclobutanes; Drug Contamination; Internet; Metals; Nonprescription D | 2013 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P | 2012 |
Multidisciplinary intervention with sibutramine: assessing successful weight loss predictors in military adolescent dependents.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Combined Modality The | 2012 |
Experimental study of the effects of Dietressa, a new weight-reducing drug.
Topics: Animals; Anti-Obesity Agents; Antibodies; Cyclobutanes; Drug Evaluation, Preclinical; Eating; Male; | 2012 |
Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Mass Index; Body Weight; Cyclob | 2012 |
[Extra pounds despite sports and diets. Genetics can also be involved].
Topics: Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Energy Metabolism; Ge | 2002 |
[The anti-obesity drug sibutramine for overweight diabetic patients. "Blood pressure is not elevated")].
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hu | 2002 |
Sibutramine and panic attacks.
Topics: Appetite Depressants; Cyclobutanes; Female; Humans; Middle Aged; Panic Disorder; Weight Loss | 2002 |
[Weight loss lowers blood pressure, lipids and blood glucose. Sibutramine also helps diabetics with weight loss].
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Melli | 2002 |
Obesity drug pipeline not so fat.
Topics: Agouti-Related Protein; alpha-MSH; Animals; Anti-Obesity Agents; Appetite; Arcuate Nucleus of Hypoth | 2003 |
Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women.
Topics: Aged; Appetite Depressants; Behavior Therapy; Body Constitution; Case-Control Studies; Cyclobutanes; | 2003 |
Ask the doctor. I took the diet drug sibutramine (Meridia) for two months but stopped when I heard that its use had been linked to some deaths. During this time I developed mitral valve regurgitation. Could this have been a side effect of Meridia?
Topics: Appetite Depressants; Cyclobutanes; Drug and Narcotic Control; Humans; Mitral Valve Insufficiency; W | 2003 |
Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria.
Topics: Adolescent; Adult; Advertising; Analysis of Variance; Appetite Depressants; Body Image; Body Mass In | 2003 |
The implementation of nutritional advice for people with diabetes.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Asian People; Body Composition; Child; Cyclobutanes; D | 2003 |
[What effect does losing weight have on hypertension?].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Contraindicati | 2003 |
Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data.
Topics: Adult; Cyclobutanes; Female; Humans; Linear Models; Male; Middle Aged; Obesity; Personality; Rorscha | 2003 |
Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
Topics: Abdomen; Adipocytes; Adult; Anti-Obesity Agents; Appetite Depressants; Body Constitution; Cyclobutan | 2004 |
Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry.
Topics: Animals; Anti-Obesity Agents; Body Composition; Calibration; Cross-Sectional Studies; Cyclobutanes; | 2004 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Evidence-Based Me | 2004 |
Combined dietary and pharmacological weight management in obese hypopituitary patients.
Topics: Adult; Anthropometry; Appetite Depressants; Blood Glucose; Body Composition; Cholesterol; Combined M | 2004 |
Does prior authorization of sibutramine improve medication compliance or weight loss?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insurance, | 2005 |
Pharmacotherapy for obesity--promise and uncertainty.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipide | 2005 |
[Reducing obesity].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutan | 2006 |
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cohort Studies; Cyclobutanes; Heart Rate; Humans; | 2007 |
Keeping weight-loss drugs in perspective. If you're dangerously overweight, diet pills may help--but not without major lifestyle changes.
Topics: Anti-Obesity Agents; Cyclobutanes; Eating; Female; Humans; Lactones; Obesity; Orlistat; Overweight; | 2006 |
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cell Line; Condition | 2006 |
Summaries for patients. Effects of drug treatment for obesity in adolescence.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Body Height; Body Mass Index; Child; Combined Mo | 2006 |
What constitutes successful weight management in adolescents?
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes; Female; | 2006 |
Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
Topics: Adult; Appetite Depressants; Coronary Disease; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitu | 2006 |
Baseline serum folate level may be a predictive factor of weight loss in a morbid-obesity-management programme.
Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Cyclobutanes; Eating; Fema | 2006 |
Incorrect use of orlistat and sibutramine in clinical practice.
Topics: Anti-Obesity Agents; Appetite Depressants; Contraindications; Cyclobutanes; Guideline Adherence; Hum | 2007 |
Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Chemistry, Pharmaceutical; Cyclobutanes; Drug and | 2007 |
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Body Weight; Cyclobuta | 2008 |
Anti-obesity drug use before professional treatment in Taiwan.
Topics: Adolescent; Adult; Age Distribution; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy | 2007 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M | 2007 |
Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Humans; Obesity; R | 2007 |
[Effect of weight loss on blood pressure].
Topics: Appetite Depressants; Behavior Therapy; Blood Pressure; Body Mass Index; Cyclobutanes; Diet, Reducin | 2007 |
Successful treatment of a morbidly obese and growth-retarded adolescent with Williams-Beuren Syndrome by combining the medication of growth hormone and sibutramine.
Topics: Adolescent; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Huma | 2008 |
[Antiobesity drugs--new limitations].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evid | 2007 |
[Struggle about the best reducing diet, Fat gone by means of more fat?].
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Mass Index | 2004 |
Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox.
Topics: Adult; Appetite Depressants; Body Mass Index; Combined Modality Therapy; Cyclobutanes; Diabetes Mell | 2008 |
Abdominal visceral fat reduction is associated with favorable changes of serum retinol binding protein-4 in nondiabetic subjects.
Topics: Adiposity; Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insulin Resist | 2008 |
Sibutramine: balancing weight loss benefit and possible cardiovascular risk.
Topics: Antidepressive Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Eating; Evidence | 2008 |
New obesity drug approved.
Topics: Antidepressive Agents; Appetite Depressants; Cyclobutanes; Humans; Obesity; United States; United St | 1998 |
Does sibutramine keep the weight off?
Topics: Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Humans; Obesity; Randomized Contro | 1999 |
New pharmacological directions for the treatment of overweight and obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Enzyme Inhibi | 1999 |
[Obesity: when does the internist recommend surgery?].
Topics: Adult; Appetite Depressants; Body Weight; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity, | 2000 |
[Evolution and weight and body composition determination after therapy for pathological obesity for measuring compliance in (re)-education].
Topics: Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet, Reducing; Electric Impedance | 2000 |
Diet drug helps keep weight off.
Topics: Appetite Depressants; Cyclobutanes; Hypertension; Obesity; Weight Loss | 2001 |
[Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Europe; Humans; Mu | 2001 |
Toward optimal health: the experts discuss weight control drugs. Interview by Jodi Godfrey Meisler.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Counseling; Cyclobutanes; Diet, Reducing | 2001 |
[Weight reduction. Doubly effective with drug support].
Topics: Appetite Depressants; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Diet, Reduc | 2001 |
Drug treatment for obesity. We need more studies in men at higher risk of coronary events.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Cholesterol, LDL; Cyclobutanes; Female; Humans | 2001 |
Drug therapy for management of obesity.
Topics: Appetite Depressants; Cholesterol, HDL; Cyclobutanes; Humans; Obesity; Randomized Controlled Trials | 2001 |
Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
Topics: Appetite Depressants; Body Mass Index; Coronary Disease; Cyclobutanes; Energy Intake; Fasting; Femal | 2001 |
Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity.
Topics: Adipose Tissue; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Fatty Acids, Non | 2001 |
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Topics: Adult; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Middle Aged; O | 2001 |
Weight loss and health-related quality of life.
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity; Placebos; Quality of Life; Randomized Controlle | 2001 |
Long-term medication use and weight loss maintenance: an observational study.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Longitudinal Studies; Obesi | 2001 |
[Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
Topics: Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Constipation; Cyclobutanes; Diabetes | 2001 |
Does long-term use of sibutramine (Meridia) result in continued weight loss in short-term responders?
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cyclobutanes; Dose-Response Relation | 2001 |
Risk factor modification through weight loss enhanced with pharmacotherapy.
Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Humans; Hyperlipidemias; | 2002 |
Can drugs help you lose weight?
Topics: Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Orlistat; Weight Loss | 2002 |
[New drugs for the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diet; Humans; Lac | 1999 |
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe?
Topics: Appetite Depressants; Cyclobutanes; Drug Combinations; Humans; Phentermine; Weight Loss | 2002 |